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Biconjugate-based therapies are becoming increasingly popular as a drug delivery 
system. Therefore, the methods for preparing bioconjugates should be sufficiently 
explored so that bioconjugates can be created in a highly selective, efficient, and robust 
fashion. This thesis will describe bioconjugation reactions mediated by unnatural amino 
acids (UAAs) as a means of preparing well-defined and selective macromolecular 
complexes. Alkyne UAA-mediated bioconjugation reactions will be reported, followed 
by the results of efforts to prepare multivalent complexes. Lastly, functionalization of the 
gene-editing protein Cas9 with UAAs will be explored. The goal of this work is to 
identify innovative, improved ways of preparing bioconjugates towards downstream 
applications of enhanced therapeutic delivery.  
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CHAPTER 1: INTRODUCTION 
Bioconjugation Chemistry 
 With widespread applications in the fields of medicine, materials, and 
pharmaceuticals, bioconjugate chemistry is a rapidly growing area of chemical research. 
Broadly defined, bioconjugates are structures composed of two or more chemically 
coupled molecules, wherein at least one molecule is a biomolecule such as a protein, 
carbohydrate, or oligonucleotide. A fluorescent probe, surface, small molecule, or other 
biomolecule serves as a reaction partner with the first molecule to yield the 
bioconjugate.1-3 Current applications of bioconjugates include fluorescent biochemical 
assays, enhanced diagnostic and 
therapeutic agentsmedical imaging, 
and industrial catalysis and 
production.1 Protein bioconjugates, 
where at least one of the conjugate 
partners is a protein, have been 
utilized to enhance drug delivery and 
cellular imaging through the use of 
antibodies conjugated to cytotoxic 
drug molecules and luminescent 
quantum dots, respectively.4-6 
A plethora of bioconjugation 
reactions available to researchers can 
be employed based on the specific Figure 1.1. Bioconjugation Reactions.
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requirements of an experiment. Common reactions involving thiol, amine, and carbonyl 
functional groups are typically employed due to their biological abundance. Thiols, when 
deprotonated to exist as thiolates, can react with haloacetamides or maleimides to create 
thioether linkages, and with existing disulfides to interchange –R groups and create new 
disulfide linkages  (Figure 1, C).1 Carbonyls such as ketones and aldehydes react with 
substituted oxyamines and hydrazines to form substituted oximes and hydrazones, 
respectively (Figure 1, A).1 An even more popular choice for some bioconjugate chemists 
is the copper-catalyzed azide alkyne cycloaddition (CuAAC), also known as the “copper 
click” reaction, wherein a terminal alkyne and azide are combined to form a highly stable 
triazole (Figure 1, B).1 Because azides and alkynes are not commonly found within 
biological systems, the CuAAC reaction requires functionalization of a biomolecule with 
an azide or alkyne linker prior to performing the bioconjugation reaction.  
Limitations of non-Biorthogonal Bioconjugation Reactions 
The preparation of covalently-linked protein bioconjugates is often accomplished 
through reaction of a protein’s native nucleophilic residues, such as lysine, cysteine, and 
serine.6,7 However, through this method, bioconjugation can occur at multiple residues 
within the protein, resulting in non-specific conjugation at a varying number of 
positions.7 Consider antibody-drug conjugates (ADCs), an important approach to cancer 
immunotherapy, which avoids the toxic effects of traditional chemotherapy treatments.8 
ADCs—which consist of an antibody coupled to a cytotoxic agent—are traditionally 
created by conjugating the antibody to a linker through the antibody’s endogenous lysine 
and cysteine residues. The drug molecule, sometimes termed the “payload,” can then be 
attached to the linker through any suitable chemical reaction as long as the link remains 
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stable until the antibody binds to the appropriate disease state antigen and the ADC enters 
the cancer cell.8 Reacting the linker-drug complex with the native lysine and cysteine 
residues of the antibody can be problematic, as the result is a heterogeneous population of 
antibody-drug conjugates with varying amounts of drug molecules conjugated to 
nonspecific residues (Figure 1.2).  For instance, Immunoglobulin G (IgG)—a widely used 
scaffold from which many monoclonal antibodies are derived—contains 80 lysine 
residues and 14 cysteine disulfide pairs.8 After reacting the antibody with a drug 
molecule, the resulting mixture of IgG-drug conjugates would have a wide range of 
potencies, and conjugates containing 
various numbers of drug molecules 
would likely differ in reactivity, 
solubility, and stability. Using a 
heterogeneous ADC mixture in a 
patient population could lead to 
unpredictable responses, and isolating a homogeneous mixture of the IgG-drug 
conjugates requires painstaking purification. 
These limitations necessitate the development of alternative, more selective 
methods to create ADCs, which include enzymatic ligations, glyco-conjugations, and 
unnatural amino acid technologies.8 Enzymatic ligation techniques hijack an enzyme’s 
ability to catalyze very specific reactions by introducing a peptide sequence in the 
antibody that binds the enzyme and directs a conjugation reaction.8-10  Glyco-conjugation 
methods create relatively homogenous ADC mixtures by conjugating the payload to 
carbohydrates that become attached to the antibody surface during post-translation 
Figure 1.2. Nonspecific conjugation of a drug to an 
antibody results in a heterogeneous product mixture. 
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glycosylation.8,11,12 Unnatural amino acids are synthetic amino acids with novel side 
chains that, when incorporated into antibodies, can conjugate with the payload in an 
orthogonal fashion that avoids cross reaction with any other endogenous amino acid.8, 13  
Unnatural Amino Acids 
 Proteins serve numerous functions in living systems, and are thus often deemed 
the “workhorses” of the cell. They catalyze reactions, provide structural support, facilitate 
molecular transport, and produce immune responses.14 Amazingly, living systems achieve 
this remarkable diversity of function with proteins that are comprised of only twenty 
naturally occurring amino acids.  
 To expand the breadth of protein function, unnatural amino acids (UAAs) can be 
synthesized and site-specifically incorporated into proteins.15 UAAs are amino acids that 
are altered to contain side chains with functional groups not found in the twenty 
canonical amino acids. The addition of these novel amino acids into a protein can 
dramatically alter its function, as UAAs with side chains acting as fluorophores, metal-
ion chelators, and spectroscopic probes have expanded the utility and properties of 
certain proteins.15 Derivatizing a protein with novel UAAs has further enabled 
researchers to track conformational changes upon ligand binding, map electron transfer 
during a redox reaction, photoactivate or photocage the protein, and even improve its 
pharmacological properties.15 
Additionally, the incorporation of UAAs with non-native chemical functional 
groups into proteins introduces a “bioorthogonal handle” that supports the previously 
discussed protein conjugation reactions. Bioorthogonal reactions are those that occur 
within a living system without interfering with the endogenous physiological processes 
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occurring within that system.16 By introducing amino acids bearing functional groups that 
do not occur naturally in proteins, we obtain much higher reaction specificity than when 
reacting amino acid residues containing native amine, thiol, or hydroxyl groups.13,16 
Through this approach, a homogenous antibody-drug conjugate, for instance, could be 
generated.   
Incorporation of Unnatural Amino Acids into Proteins 
The Central Dogma of Biology 
  The central dogma of molecular biology refers to the process by which DNA is 
transcribed to RNA, which is subsequently translated to protein (Figure 1.3). 17 This 
process describes the flow of information from 
stored genetic material to active protein function.17 
The first step of the central dogma, transcription, 
involves converting double-stranded DNA to 
single-stranded messenger RNA (mRNA) via RNA 
polymerase.18 In eukaryotic organisms, additional 
splicing steps—which increase genetic diversity—
occur to generate a processed mRNA molecule. 
Next, mRNA, which is comprised of 3-nucleotide 
codons, is translated to a polypeptide chain at the 
ribosome (Figure 1.4). Translation initiates with the 
mRNA start codon AUG, which codes for the amino acid methionine. An amino-acyl 
tRNA synthetase specific to methionine will attach the amino acid to a corresponding 
tRNA in a process known as “charging.” This methionine-specific tRNA contains a 
Figure 1.3. The central dogma of 
molecular biology describes the 
flow of information from DNA to 
RNA to protein.19 
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Figure 1.4. Translation of 
mRNA (red) into a 
polypeptide chain is 
accomplished at the ribosome 
(teal). The anticodon of the 
aminoacyl tRNA (gold) will 
hybridize with the mRNA 
codon, allowing the amino 
acid to be added to the 
growing peptide chain. 20 
three-base anticodon that hybridizes to the mRNA start codon. As the ribosome continues 
to decode the mRNA codons, amino-acyl tRNAs continue to add amino acids to the 
growing peptide chain. Each tRNA/synthetase pair is only capable of charging a specific 
amino acid, which confers sequence specificity to the translation process. Termination of 
the peptide chain occurs when a stop codon, which corresponds to a peptide release 
factor, in the mRNA is reached. Following termination, the peptide will undergo post-









The Schultz Method for Incorporation of Unnatural Amino Acids 
Incorporation of an unnatural amino acid into a protein can be most efficiently 
accomplished by a method developed in Peter Schultz’s laboratory.21 This method, 
known as amber suppression, relies on the inherent transcriptional and translational 
machinery in living organisms. The process is shown in Figure 1.5 (right) in contrast to 
the process of natural amino acid incorporation (left). Expression of UAA-containing 
proteins described in this thesis requires an evolved orthogonal amino-acyl synthetase 
(aaRS)/tRNA pair isolated from the archaea Methanococcus jannaschi.22 An orthogonal 
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aaRS/tRNA pair is one in which the aaRS does not charge any endogenous tRNAs, and 










 The orthogonal aaRS/tRNA pair can charge the specific unnatural amino acid for which 
it has been evolved, and subsequently incorporate the UAA in response to the amber stop 
codon, TAG. Thus, site-specific insertion of a UAA also requires that the DNA sequence 
encoding the UAA be mutated to TAG prior to expression of protein. 
This incorporation method, which has been optimized for expression of UAA-
containing protein in the bacteria E. coli, begins with transformation of two plasmids into 
competent E. coli cells. One plasmid contains a gene that encodes the protein of interest, 
which will have a TAG codon at the desired location of UAA incorporation. This plasmid 
also contains a gene conferring antibiotic resistance, most often to the antibiotic 
ampicillin. The second plasmid contains genes encoding the orthogonal tRNA/aaRS pair 
and chloramphenicol acetyltransferase, which confers resistance to the antibiotic 
chloramphenicol. When both plasmids are transformed into E. coli and plated on agar 
 
Figure 1.5. Mechanism for 
incorporation of an unnatural 
amino acid (UAA) into a 
growing peptide chain. An 
orthogonal amino-acyl 
synthetase (aaRS)/tRNA pair 
will introduce the UAA at the 
site of a stop codon (TAG). 
In the absence of unnatural 
amino acid, translation halts, 
resulting in non-functional 
protein.23 
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containing ampicillin and chloramphenicol, only cells containing both plasmids will 
survive. 
Expression of the gene encoding the protein of interest is controlled by a promoter 
induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG), and the gene 
encoding the tRNA/aaRS pair is controlled by an arabinose-inducing promoter. Thus, 
expression of mutant UAA-containing protein will occur in the presence of arabinose, 
IPTG, ampicillin, chloramphenicol, and the unnatural amino acid. Figure 1.6 depicts the 






Bioorthogonal Bioconjugation Reactions Utilizing Unnatural Amino Acids 
Hundreds of unnatural amino acids, each conferring specific new functions to 
proteins—have been prepared and added into an ever-growing library of synthetic amino 
acids.24 Of particular interest, however, are those that introduce a bioorthogonal handle 
into proteins to support different bioconjugation reactions. Unnatural amino acids falling 
into this category most commonly include those containing carbonyl, azido, iodo, or 
alkynyl moieties, as these functional groups are not found endogenously in proteins. 
 
Figure 1.6. Incorporation of a UAA into GFP requires cotransformation of a protein-encoding 
plasmid and aaRS/tRNA-encoding plasmid into E. coli. 































Figure 1.7. Structures of unnatural amino acids employed in biorthogonal conjugation reactions. 
R H2






























A carbonyl-containing amino acid, such as p-acetylphenylalanine (pAcF) supports 
both oxime and hydrazone ligation reactions.25 (Figure 1.1, A). The azido amino acid p-
azidophenylalanine (pAzF) can be reacted with a terminal alkyne in the copper-catalyzed 
azide alkyne cyloaddition reaction (CuAAC), affording the stable triazole25 (Figure 1.1, 
B). The iodo-containing UAA pIF supports the palladium-catalyzed Sonogashira cross-




(pEtF)—two amino acids 
harboring terminal alkynes—can 
support the Glaser-Hay reaction, 
wherein two terminal alkynes are 
reacted in the presence of a 
copper catalyst to yield an 
internal diyne (Figure 1.8). 27 
Most recently, amino acids containing a bromoalkyne moiety (pBrPrF, pBrEtF) have 
been introduced into proteins and reacted via the Cadiot-Chodkiewicz coupling of a 
Figure 1.8. Additional biorthogonal bioconjugation reactions.  
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terminal alkyne and haloalkyne, yielding the same diyne product as the Glaser-Hay 
reaction but under milder reaction conditions28  (Figure 1.8).  
Conclusion 
The utilization of unnatural amino acids to transform the function of proteins has 
made a substantial impact on the field of bioconjugate chemistry. Through the 
introduction of synthetic amino acids into protein, bioorthogonal conjugation reactions 
can be achieved, enhancing both the specificity and efficiency of bioconjugate 
preparation. The range of conjugation reactions employed in biological systems can thus 
be expanded to include those that react carbonyl, azide, alkyne, iodo, and haloalkyne 
functional groups.25-28 This thesis will describe the synthesis and introduction of novel 
bromoalkyne UAAs into the amino acid repertoire, as well as the implementation of these 
UAAs in a new bioconjugation reaction. The systematic optimization of the UAA-
enabled Glaser-Hay reaction will next be explored, followed by a report of initial efforts 
to prepare multivalent, multifunctional bioconjugates. Lastly, the functionality of a gene-
editing protein will be investigated using unnatural amino acids. It is our hope that the 
experiments reported here will expand the base of knowledge relevant to bioconjugate 
chemistry and unnatural amino acid technology, thus enabling downstream applications 
in medicine and biochemistry.  
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The incorporation of an unnatural amino acid bearing a chemical moiety not 
found within the twenty naturally occurring amino acids conveys many advantages for 
chemical biologists. Within the context of protein bioconjugations, it provides two 
distinct benefits. First, it provides a specific site for selective conjugation of the protein. 
Second, it allows access to several useful chemistries previously unavailable for direct 
bioconjugation reactions involving proteins.1, 2 The development of unnatural amino acids 
bearing terminal alkynes has expanded the breadth of direct biorthogonal protein 
reactions to include terminal alkyne couplings. Of these reactions, the Glaser-Hay 
coupling of two terminal alkynes is of specific interest to us. This coupling reaction 
affords a well-defined, linear 1,3-diyne via a copper (I) catalyst and bidentate nitrogenous 
ligand (Figure 2.1), most often N,N,N’,N’-	  tetramethylethylenediamine (TMEDA). 3-6  
 
 
Moreover, this reaction generates a new carbon-carbon bond that is highly stable 
and unreactive under typical physiological conditions.3 Diynes and other conjugated 
acetylenic structures generated from the Glaser-Hay coupling reaction have many useful 
applications. Examples of the Glaser-Hay reaction being employed include the 
preparation of diacetylenes utilized in crystal-forming polymerization reactions, or the 
synthesis of macrocyclic compounds with diverse applications in supramolecular 
Figure 2.1. Overall Glaser-Hay homocoupling reaction scheme. 
	   15 
chemistry and nanotechnology.7-9 Additionally, these diynes are the starting point for 
many cycloaddition reactions yielding carbo- and hetero- cycles that display interesting 
biological, optoelectronic, and photochemical properties.10-14  
Previous work by Lampkowski et al. demonstrated the first successful biological 
Glaser-Hay coupling in a full-length protein and under mild reaction conditions (Figure 
2.2).15 With incorporation of alkynyl UAA p-propargyloxyphenylalanine (pPrF, Figure 
2.2, 1) into green fluorescent protein (GFP) at position 151, researchers prepared a 






Despite having successfully employed the Glaser-Hay coupling in a biological 
context, noticeable protein degradation occurred after about 6 h. This degradation is 
potentially due to hydroxyl radicals generated from the copper (II)-hydroxyl intermediate 
in the catalytic cycle of the Glaser-Hay reaction, which are known to be deleterious to 
living systems (Figure 2.3).4, 17. Lampkowski et al. characterized this protein oxidation by 
MS analysis, demonstrating an ultimate loss of protein product.15 To improve this 
reaction and limit protein degradation, we became interested in developing means to 
Figure 2.2. 16 
A) Structure of alkynyl 
unnatural amino acid p-
propargyloxyphenylalani
ne  (pPrF).  
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Figure 2.3. Computationally-generated proposed mechanism for the Glaser-Hay reaction. 3 
	  
circumvent the production of harmful radical species while generating the same internal 











coupling of a terminal alkyne 
and halo-alkyne represents a 
viable alternative to the 
Glaser-Hay coupling 
reaction. While a key 
component of the Glaser–
Hay mechanism is the 
formation of a copper(II)-
Figure 2.4. Proposed mechanism of the Cadiot-Chodkiewicz 
coupling reaction.18 
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Figure 2.5. Structures of UAAs employed in bioconjugation reactions. 
hydroxyl intermediate, the Cadiot–Chodkiewicz reaction is thought to cycle between the 
copper (I) and copper (III) states while avoiding the harmful copper (II) state (Figure 
2.4).17-19   
We thus reasoned that the chemistry could be employed in a biological context to 
minimize previously observed oxidative damage of the Glaser-Hay reaction. 
Furthermore, the reaction is highly chemoselective, as the use of a halo-alkyne minimizes 
the formation of homodimer side products by differentiating the two alkynes. Together, 
these two facts have the potential to increase the yield of the desired bioconjugate. 
Herein, we describe the development of a protein-fluorophore bioconjugate linked 
through an internal 1,3-diyne generated via the Cadiot-Chodkiewicz coupling reaction. 
Results and Discussion 
In order to conduct and optimize a Cadiot–Chodkiewicz bioconjugation, new 
UAAs harboring a terminal haloalkyne needed to be synthesized and incorporated into a 
protein. In order to probe UAA-dependent effects on the reaction, aliphatic and aromatic 
brominated alkynyl UAAs were prepared from the previously reported protected p-
propargyloxyphenylalanine (pPrF, Figure 2.5, 1) and p-ethynylphenylalanine (pEtF, 
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R H R Br
NBS, AgNO3
Acetone
Several different bromination protocols from the literature were examined in 
order to generate a bromoalkyne. Phenylacetylene was used as a low-cost model substrate 
until the highest-yielding bromination reaction was established. First, bromination was 
attempted by combining phenylacetylene with liquid bromine in the presence of four 
equivalents of potassium hydroxide. This procedure, however, generated minimal 
brominated product. Next, bromination of a phenylacetylene using N-bromosuccinamide 
(NBS) and catalytic silver nitrate was performed (Figure 2.6). This reaction worked well, 




Gratifyingly, bromination under NBS also worked well for the synthesis of both 
UAAs in moderate yields.22,23 Following deprotection, the final UAAs, p-bromo-
propargyloxyphenylalanine (pBrPrF, Figure 2.5, 3) and p-bromo-ethynylphenylalanine 
(pBrEtF, Figure 2.5, 4), were recovered in overall good yields (67% and 34% 
respectively) and in high purity. 
With the pBrPrF and pBrEtF in hand, it was necessary to incorporate these UAAs 
into a model protein. Due to both its fluorescent properties and well-documented prior 
use in UAA development technologies, green fluorescent protein (GFP) was selected as a 
model system. Specifically, attempts were made to incorporate newly synthesized UAAs 
at residue 151 by suppressing the amber stop codon. Furthermore, our previous work 
immobilizing GFP revealed that this surface exposed site is ideal for UAA placement, as 
Figure 2.6. Reaction scheme for the bromination of terminal alkynes. 
	   19 
Figure 2.7. A) Successful 
incorporation of pBrPrF and 
pBrEtF into GFP at residue 151 
via aaRS pCNF was confirmed 
with a protein band at ~26 kDa 
following SDS-PAGE analysis. 
B) Data from 
spectrophotometric analysis 
were compared to a negative 
control (-) representing 
background incorporation as 
well as the previously reported 
alkyne UAAs pPrF and pEtF.  
	  
the rigidity of the residue helps orient the bioorthogonal functional handle.24 In lieu of 
undergoing a tedious aaRS selection process, we hoped to incorporate the brominated 
UAAs using the previously described promiscuous pCNF aaRS.25,26  The pCNF aaRS was 
investigated first to incorporate pBrPrF and pBrEtF due to their structural similarity to 
other UAAs that the pCNF aaRS incorporates.  
The pCNF aaRS incorporated both brominated-UAA variants with a higher 
fidelity than the simple terminal alkyne analogs (Figure 2.7). As expected, the smaller 
pBrEtF UAA, had a higher incorporation than the pBrPrF. We hypothesize that the 1-
bromo-alkyne moiety provides a degree of hydrophobic character to the UAA, making 
the interaction between the amino acid and the hydrophobic binding pocket of the aaRS 
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With both brominated alkyne UAAs in hand, it was feasible to develop a 
bioorthogonal Cadiot–Chodkiewicz reaction. Initial studies employed the pBrPrF-
containing GFP variant, to mimic previous Glaser–Hay pPrF-GFP studies and provide an 
effective comparison. The Cadiot–Chodkiewicz reaction was carried out in PBS (pH = 7) 
using copper iodide and triethylamine (TEA) (both at a final concentration of 5 mM) in 
the presence of a terminal alkyne-containing fluorophore (AlexaFluor 488 alkyne, Figure 
2.8, A, right) at 4°C for 6 h. The reaction was successful, as fluorescence could be 
detected on a denatured SDS-PAGE gel only when protein and fluorophore were exposed 
to the CuI/TEA system (Figure 2.8, A, left). Even more exciting was the minimal protein 
degradation relative to the previously reported Glaser–Hay reaction. Also, due to the 
chemoselective nature of the reaction no protein dimerization was detected, and 









Figure 2.8. A) A 
bioorthogonal Cadiot-
Chodkiewicz reaction 
was performed on 
GFP/pBrPrF and Alexa 
FlourTM 488 Alkyne 
(structure shown at top 
right) in the presence 
(lane 1) and absence 
(lane 2) of CuI and TEA 
at 4°C for 4 hours.8 B) 
Reaction profile at 4°C 
over a 24 h time period. 
Following analysis via 
SDS-PAGE, fluorescent 
imaging, and staining 
with coomassie blue, 
protein levels were 
normalized to the 0 time 
point control.  
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In attempt to further optimize the reaction, both copper concentrations and 
temperatures were varied. A 5 mM working Cu(I) concentration was found to be ideal, 
which represents a marked improvement over the 50 mM concentrations required for the 
previously discovered Glaser–Hay reaction. Numerous reports have indicated that in vivo 
use of copper-mediated bioorthogonal chemistries required working concentrations of 
near 0.1 mM of copper(I) salt to minimize cytotoxicity.27,28 Thus, the minimized copper 
concentrations help bring bioorthogonal conjugated diyne chemistry into the range of in 
vivo use. These copper concentrations also had no impact on GFP fluorescence as 
determined by control reactions. Additionally, the optimal temperature profile for the 
reaction was also investigated. After performing a time course of the reaction at both 
37°C and 4°C, we were able to determine very little difference between either 
temperature at early time-points. However, as the reaction was extended to 24 h, greater 
protein degradation at 37°C occurred, most likely due to an increase in the rate of 
disproportionation of the Cu(I) catalyst at this temperature, producing a reactive 
copper(II) species. However, for the 4°C temperature profile the reaction reached 
approximately 86% completion in 4 h with minimal protein degradation, indicating that 
the bioorthogonal Cadiot–Chodkiewicz reaction can be performed quickly and in a 
relatively mild conditions (Figure 2.8, B). Extended times and temperatures resulted in 
higher yields, but were accompanied by protein degradation.  
We next sought to explore the effects of an aromatic variant of the pBrPrF. As 
such, GFP151-pBrEtF was expressed, and subjected to coupling conditions at 4°C in the 
presence of an alkyne fluorophore. Once again, a successful conjugation was observed as 
determined by SDS-PAGE. Only samples exposed to the CuI/TEA system exhibited 
















pBrPrF"CC" pBrEtF"CC" pPrF"GH" pEtF"GH"
fluorescence while other controls did not, indicating the fluorescence was not due to non-
specific interactions. Interestingly, the use of an aromatic containing bromoalkyne 
appears to be less effective in the Cadiot–Chodkiewicz reaction than its aliphatic analog.  
Next we became interested in exploring how the novel biological Cadiot–
Chodkiewicz conjugation compared to our previously described Glaser–Hay reactions. In 
direct comparison, the Cadiot–Chodkiewicz exhibited far less protein degradation as 
compared to the Glaser–Hay versions of either an aliphatic (pPrF) or aromatic (pEtF) 
terminal alkyne containing UAAs. Furthermore, the data indicates that the biological 
Cadiot–Chodkiewicz reaction proceeds at a faster rate than the Glaser–Hay, with the 







Gratifyingly, these results correlate well with the mechanistic understanding of 
both reactions, as the Cadiot–Chodkiewicz requires a single copper atom, while the 
Glaser–Hay necessitates two copper–alkyne conjugates to form the diyne product. 
Figure 2.9. Reactions were conducted either under the described Cadiot–Chodkiewicz conditions 
or the Glaser–Hay conditions at 4°C depending on incorporated UAA. Due to differences in protein levels 
resulting from oxidative damage, the ratio of fluorophore coupling for each data set was normalized to the 
24-hour time point in order to compare coupling trends between reactions. 
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Moreover, the Cu(I)/(III) redox couple of the Cadiot–Chodkiewicz reaction most likely 
aids in the minimized protein oxidation relative to the Glaser–Hay coupling that involves 
a reactive Cu(II) intermediate. However, it is important to note that the Cadiot–
Chodkiewicz requires brominated UAAs, requiring additional synthetic preparation. In 
comparison to other bioconjugation techniques, the Cadiot–Chodkiewicz reaction may be 
slower; however, it employs more synthetically accessible UAAs and results in a well-
defined linear geometry primed for further reactions. Thus, the selection of the Cadiot–
Chodkiewicz reaction may be dependent on the downstream application and available 
resources.  
Overall, we have accomplished the successful application of the Cadiot–
Chodkiewicz reaction to a biological context.29 Furthermore, we have demonstrated that 
the reaction can be performed with minimal protein oxidation. Finally, we have shown 
that the Cadiot–Chodkiewicz variant requires less harsh copper(I) concentrations, 
bringing the reaction near the range for in vivo use. Future work will involve optimization 
of conditions to increase the compatibility of the reaction with biological systems, and 
extension of the reaction towards in vivo applications.  
Materials and Methods 
General: General Solvents and reagents, including the AlexaFluor 488 Alkyne, were 
obtained from Sigma Aldrich or Acros Organics and used without further purification. 
Plasmids were provided by the laboratory of Dr. Peter Schultz at The Scripps Research 
Institute. Reactions were conducted under ambient atmosphere with solvents directly 
from the manufacturer without further purification. All proteins were purified according 
to manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. Compound purities 
	   24 
were assessed by NMR and found to be 90% or greater for all compounds. All NMRs 
were acquired on an Agilent Technologies 400 MHz NMR. Compound purities were 
assessed by NMR and found to be 90% or greater for all compounds. MS analysis was 
conducted on a Thermo Finnigan LCQ Deca Quadropole Ion Trap via direct injection of 
samples at 100 µM in a 1:1 H2O/MeOH solution. Unless indicated otherwise, all 
solutions were prepared in deionized water (pH ~ 7).  
Synthesis of p-bromopropargyloxyphenylalanine (pBrPrF):  
p-Propargyloxyphenylalanine (pPrF, 0.050g, 0.150 mmol) was synthesized according to 
the literature21, and dissolved in acetone (5 mL). This solution was then transferred to a 
vial containing AgNO3 (0.03g, 0.015 mmol) and N-bromosuccinamide (NBS, 0.030g, 
0.165 mmol). The mixture was allowed to stir for 3 hours at room temperature, after 
which it was diluted with hexanes (10 mL) and the resulting crystals were filtered off. 
The filtrate was then evaporated under reduced pressure and purified via flash 
chromatography (5:1 hexanes/ethyl acetate) yielding the desired product as a white 
crystal (0.042 g, 0.102 mmol, 68% yield). The product was then subjected to 1M LiOH in 
dioxanes (500 µL each) on ice, and then stirred for two hours at room temperature. The 
LiOH/dioxanes were subsequently rotovapped off. An additional 1 mL of deionized 
water was then added to the dry product, and this solution was then brought to a pH = 4. 
The solution was extracted in ethyl acetate, dried with MgSO4, filtered and evaporated 
under pressure to dryness. A 1 mL solution 2% trifluoroacetic acid (TFA) in dimethylene 
chloride (DCM) was then added to the vial, and this mixture was allowed to stir at room 
temperature for 1 hour, and the solution was then evaporated under pressure to dryness to 
yield the final product as a yellowish crystal (0.030g, 0.101 mmol, 99% yield, 67% 
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overall yield). 1H NMR (400 MHz, CD3OD): δ 7.19 (d, J =8 Hz, 2H), 6.93 (d, J = 8 Hz, 
2H), 4.91 (s, 1 H), 4.14 (m 1 H), 3.06 (m, 2 H). 13C NMR (400 MHz, CD3OD): δ 168.4, 
155.7, 128.6, 125.4, 113.5, 73.4, 54.4, 52.3, 45.4, 25.4; MS: calcd for C12H13BrNO3: 
299.14, found 298.1 and 300.1.  
 
Synthesis of p-bromoethynylphenylalanine (pBrEtF):  
p-ethynylphenylalanine (pEtF, 0.052g, 0.171 mmol) was synthesized according to the 
literature20, and dissolved in acetone (5 mL). This solution was then transferred to a vial 
containing AgNO3 (~0.03g, 0.0171 mmol) and N-bromosuccinamide (NBS, 0.034g, 
0.189 mmol). The mixture was allowed to stir for 3 hours at room temperature, after 
which it was diluted with hexanes (10 mL) and the resulting crystals were filtered off. 
The filtrate was then evaporated under reduced pressure and purified via flash 
chromatography (3:1 hexanes/ethyl acetate) yielding the desired product as a yellow 
crystal (0.024 g, 0.063 mmol, 38% yield). The product was then subjected to 1M LiOH in 
dioxanes (500 µL each) on ice, and then stirred for two hours at room temperature. The 
LiOH/dioxanes were subsequently rotovapped off. An additional 1 mL of deionized 
water was then added to the dry product, and this solution was then brought to a pH = 4. 
The solution was extracted in ethyl acetate, dried with MgSO4, filtered and evaporated 
under pressure to dryness. A 1 mL solution 2% trifluoroacetic acid (TFA) in dimethylene 
chloride (DCM) was then added to the vial, and this mixture was allowed to stir at room 
temperature for 1 hour, and the solution was then evaporated under pressure to dryness to 
yield the final product as a yellowish crystal (0.015g, 0.056 mmol, 89% yield, 34% 
overall yield). 1H NMR (400 MHz, CD3OD): δ 7.35 (d, J = 8 Hz, 2H), 7.21 (d, J = 8 Hz, 
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2H), 4.34 (m, 1H), 3.16 (m, 2H), 2.90 (m, 2H). 13C NMR (400 MHz, CD3OD): δ 173.63, 
138.42, 132.16, 131.4, 129.2, 79.2, 54.6, 37.2, 27.22; MS: calcd for C11H11BrNO2: 
269.12, found 268.1 and 270.1. 
 
Expression of UAA-containing GFP-151 (adapted from the literature20): Escherichia 
coli BL21(DE3) cells were co-transformed with a pET-GFP-TAG-151 plasmid (0.5 µL) 
and pEVOL-pCNF plasmid (0.5 µL) using an Eppendorf electroporator. Cells were then 
plated on LB-agar plates supplemented with ampicillin (50 mg/mL) and chloramphenicol 
(34 mg/mL) and grown at 37℃. After 16 h, a single colony was selected and used to 
inoculate LB media (4 mL) supplemented with ampicillin and chloramphenicol. The 
culture was grown to confluence at 37℃ over 16 h. This culture was then used to begin 
an expression culture in LB media (20 mL) at OD600 = 0.1, then incubated at 37℃ until 
an OD600 ~0.7 was obtained. At this point, the cells were then spun down at 4℃ at 
5000rpm for 10 mins. The supernatant was dumped out and the cells were gently 
resuspended in 4 mL of LB media. To this was added ampicillin and chloramphenicol (4 
µL each), 1M IPTG (4 µL), 20% arabinose (4 µL), and 100mM of the UAA (40 µL). 
Induced cells were grown for an additional 16 h at 37℃, then harvested via centrifugation 
(10 min at 5000 rpm). The media was decanted and the cell pellet was placed in the -80℃ 
freezer for 20 min. Purification of the UAA-containing GFP was then accomplished 
using commercially available Ni-NTA spin columns according to the manufacturer’s 
protocol. Protein yield and purity was then assessed by SDS-PAGE and 
spectrophotometrically by using a Nanodrop spectrophotometer. Protein was then 
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transferred into phosphate-buffered saline solution (PBS, pH = 7) using 10k MWCO spin 
columns prior to use in the biological Cadiot-Chodkiewicz coupling. 
 
General Protocol for the Biological Cadiot-Chodkiewicz Coupling: To a sterile 1.5 
mL Eppendorf tube, the following was added in order: 10 µL of bromoalkyne UAA-
containing GFP151 (~0.5 mg/mL), 5 µL of a vigorously shaken CuI solution (50 mM), 2 
µL of trimethylamine (TEA, 50 mM), 5 µL of 488-Alexafluor alkyne (1 mM in DMSO), 
and 3 µL of PBS (pH = 7). Control reactions were set up in the absence of CuI and TEA 
and with the addition of a total of 10 µL of PBS. Reactions were performed at various 
temperatures and times as indicated in the main manuscript, with the 4℃ for 6 hr variant 
being the ideal reaction conditions.  
 
General Protocol for the Biological Glaser-Hay Coupling: To a sterile 1.5 mL 
Eppendorf tube, the following was added in order: 10 µL of termainl alkyne UAA-
containing GFP151 (~0.5 mg/mL), 5 µL of a vigorously shaken CuI solution (500 mM), 2 
µL of trimethylethylenediamine (TMEDA, 500 mM), 5 µL of 488-Alexafluor alkyne (1 
mM in DMSO), and 3 µL of PBS (pH = 7). Control reactions were set up in the absence 
of CuI and TMEDA and with the addition of a total of 10 µL of PBS. Reactions were 
performed at 4℃ for various times as indicated in the main manuscript. 
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CHAPTER 3: SYSTEMATIC OPTIMIZATION OF GLASER-HAY 
BIOCONJUGATIONS 
Introduction 
Previous work by Lampkowski et al. demonstrated the first successful biological 
Glaser-Hay coupling of a full-length protein and under mild reaction conditions.1 
However, oxidative damage incurred by copper(II)-hydroxyl intermediates resulted in a 
loss of protein product., necessitating further research to increase the applicability of the 
methodology.1 As discussed in Chapter 2, we implemented the Cadiot-Chodkiewicz 
coupling of a terminal alkyne and halo-alkyne as an improvement over the previously 
reported Glaser-Hay bioconjugation reaction. This approach avoided the harmful 
copper(II) oxidation state, required less catalytic copper, and resulted in an overall 
increased product yield.2  While the Cadiot-Chodkiewicz coupling occurred with less 
protein degradation, it did require additional synthetic steps to access bromoalkyne amino 
acids or brominated coupling partners. Because the terminal alkyne amino acid is 
commercially available, and an orthogonal aaRS/tRNA pair has specifically been evolved 
to incorporate it, the Glaser-Hay coupling may be more accessible.3 Thus, we aim to 
systematically optimize the previously developed Glaser-Hay bioconjugation to increase 
coupling efficiency and preserve protein from degradation, allowing it to find more 
widespread utility. 
Results and Discussion 
In order to further optimize the biological Glaser-Hay reaction (Figure 3.1, A), a 
250 mL expression of GFP harbouring pPrF (Figure 3.1, B) in position 151 was 
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performed to ensure that all reactions were conducted on the same protein batch (1.0 




With the GFP151/pPrF in hand, a range of experimental variables was examined 
in a systematic fashion when reacting the mutant GFP with an AlexaFluor-488 alkyne 
dye. Due to the production of biologically deleterious Cu(II) in the catalytic cycle, we 
examined the addition of both reducing agents and radical scavengers to the reaction as a 
mechanism to mitigate the potential damage caused by the radicals initiated by the Cu(II) 
species. Additionally, we examined the effects of a wide variety of copper sources and 
ligands to further activate the copper center, as well as buffers at varying pH. Finally, 
reaction times and temperatures were varied to further achieve favorable coupling with 
limited degradation. Each variable was independently varied based on the previously 
reported conditions, and optimized conditions were then screened in combination to 
elucidate the best Glaser-Hay bioconjugation conditions.  
Initial studies examined the addition of reducing agents to the reaction to reduce 
harmful Cu(II) back to the Cu(I) species. Based on their biological compatibility, β-
mercaptoethanol, tris-(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT) and 
nicotinamide adenine dinucleotide (NADH) were selected for analysis. Glaser-Hay 
reactions were conducted with the GFP/pPrF and AlexaFluor-488 alkyne in the presence 
of a reducing agent (500 mM), TMEDA and CuI for 4 h at 4°C. Control reactions were 
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also performed in the absence of reducing agent, or in the absence of the CuI/TMEDA. 
After purification and buffer exchange, the reactions were analyzed by SDS-PAGE for 
protein degradation and coupling efficiency. Fluorescence intensity indicated the 
effective coupling reaction as the GFP is denatured and no longer fluorescent, while the 
coupling to the fluorophore re-establishes a fluorescent signal. Coomassie staining was 
also performed to determine protein purity and relative degradation. Coupling efficiency 
was determined from the ratio of fluorescence to Coomassie staining, and ratios greater 
than 1 indicate an improvement over the previously published conditions. For each 
reaction, background fluorescence and Coomassie staining was removed prior to 
performing calculations. Unfortunately, no reducing agent afforded better coupling 
conditions than the originally published conditions, and DTT dramatically inhibited 










Figure 3.2. Effect of reducing agents on coupling. Ratios indicate that the 
previously published conditions (lane 2) are superior. 














 Similar results were observed when radical scavengers were employed including 
cysteine, oleic acid, and ascorbic acid (Figure 3.4). Ascorbic acid also hindered the 
Glaser-Hay reaction from occurring and increased the level of protein degradation 






Based on the literature, a variety of copper sources have been utilized in the 
Glaser-Hay reaction, and we next investigated if any were more advantageous than the 
previously reported copper iodide. Reactions were performed using copper(I) iodide, 
copper(I) chloride, copper(II) chloride, and copper(II) sulfate. Reactions were 
additionally performed using copper(II) chloride with reducing agent NADH and 
copper(II) sulfate with NADH dinucleotide to test whether a copper(II) catalyst reduced 
to copper(I) would be advantageous for the reaction. None of these copper sources were 
able to outperform the previously established CuI, as determined by SDS-PAGE (Figure 
3.5). 
 
Figure 3.4. Effect of radical scavengers on coupling. 
Ratios indicate that the previously published 
conditions (lane 1) are superior. 
Figure 3.3. Structures of 
radical scavengers. 
















Additional elements, which have shown promise in the literature for improving 
the yield Glaser-Hay reactions, were tested as well. Addition of a soluble Ni cocatalyst—
Ni(NO3)2!6H2O—which was reported to improve Glaser-Hay reaction rates,4a-b resulted 
in nearly total degradation of the protein. Because the Glaser-Hay mechanism relies on an 
oxidant, we reasoned that bubbling air through the reaction mixture may facilitate the 
reaction, although the result was substantial loss of protein and minimal coupling.	   
 We next investigated the effect of the ligand on the Glaser-Hay bioconjugation. 
Early attempts with nitrogenous monodentate ligands (TEA, pyrrolidine, etc.) did not 
lead to substantial coupling, and a more thorough investigation of nine bidentate 
nitrogenous ligands followed (Figure 3.6).	   	  Ligands 3 and 4 were selected to investigate 
the optimal chelation ring size, and 5, 6, and 7 were employed to probe the substitution of 
the nitrogen atom. Finally, 8 and 9 were selected to alter the electronic environment of 
the nitrogen atoms, while simultaneously testing the necessity of chelation. All ligands 
were screened in comparison to 2 (TMEDA), the ligand used in our previously published 
experiments.  
Figure 3.5. Effect of copper source on coupling. Ratios indicate that the 
previously published conditions (lane 1) are superior. 




































Initial trials did not result in any superior ligand to 2 (Figure 3.7). However, additional 
replicates showed that the 2,2-dipyridyl ligand (8) produced a nearly 4-fold increase in 
coupling efficiency (Figure 
3.8, lane 4). Because 8 is 
primarily soluble in organic 
solvents, which can be 
detrimental to proteins in high 
concentrations, we reasoned 
that 10, a 2,2-dipyridyl ligand 
containing two carboxylic 
acid functionalities, might increase solubility in aqueous media and overcome this 
limitation. Ligand 10 only partially dissolved in pure water, which initially led to protein 
degradation and non-optimal coupling upon reaction (Figure 3.8, lane 2). However, 
treatment of 10 with NaOH effectively produced the deprotonated form of the ligand, 
which allowed for full solubility in water.  
Figure 3.6. Structures of ligands used in optimization studies. 
Figure 3.7. Effect of nitrogenous ligand on coupling. Ratios indicate 
that the previously published conditions (lane 1) are superior. 
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Figure 3.8. Comparison of 
dipyridyl nitrogenous ligands. 
Ratios indicate that 8 and 10 
result in increased coupling 
over the previously published 
conditions (lane 1), though poor 
solubility of 10 resulted in 









When fully solubilized, 10 afforded a coupling efficiency nearly 7 times greater than that 
of 2 (Figure 3.9, lane 7). We hypothesize that the combination of the electronic effects of 
the bipyridyl ligand coupled with the rigidity of the ligand aided in the chelation and 








After elucidating that ligand 10 resulted in superior coupling, we explored 
whether other copper sources, radical scavengers, or reducing agents would further 
increase the coupling efficiency with this ligand. Varying these other conditions did not 
afford enhanced results, as copper(I) iodide with no added agents remained the best 
condition using either 2 or 10.  
Figure 3.9. Comparison 
of dipyridyl nitrogenous 
ligands, with and without 
addition of reducing 
agent TCEP. Results 
indicate that in the 
absence of TCEP, 
ligands 8 and 10 show 
increased coupling over 
the previously published 
conditions (lane 2). 
Furthermore, by fully 
solubilizing ligand 10, 
coupling is enhanced and 
degradation is reduced. 
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The next variable examined was the effect of solution pH on the reaction. GFP 
was buffer exchanged into PBS at pH 6.0, pH 7.0, pH 8.0, and pH 9.0. Both the original 
ligand (2) and 10 were used for 
Glaser-Hay couplings in each pH 
solution. Interestingly, reactions 
employing 10 exhibited the best 
balance of increased coupling and 
decreased degradation at pH 8.0 
(Figure 3.10). A likely explanation 
is that this slight pH increase favors the deprotonated state of the carboxylated ligand, 
which may result in better aqueous solubility of the ligand. Increasing the pH to 9, 
however, may result in more degradation as this environment is likely too basic for the 
protein to retain proper folding. 
 Reactions with 2, however, had the 
highest Glaser-Hay coupling at pH 6.0 (Figure 
3.11). This finding may be explained by the 
computationally generated mechanism of the 
Glaser-Hay reaction (see Chapter 2, Figure 
2.3).5 Lowering the pH would favor 
protonation of the hydroxyl group attached to 
the copper center, which would facilitate 
formation of water as a leaving group and allow for easier regeneration of the copper-
ligand catalytic structure.  
Figure 3.10. Effect of pH with ligand 10 on coupling. 
Results indicate that optimal coupling occurs at pH 8 when 
ligand 10 is used. Ligand 10 at all pH points represents an 
increase in coupling over previously published conditions 
(lane 1). 
	  
Figure 3.11. Effect of pH with ligand 2 on 
coupling. Results indicate that optimal coupling 
occurs at pH 6 when ligand 2 is used, which 
represents an increase over the previously 
published conditions (lane 2). 
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 Additionally, due to the decreased oxidative damage, we then employed these 
conditions at different temperatures to see if coupling ratios could be increased further, as 
the previously published conditions were performed at 4°C to minimize degradation. 
Identical reactions with both ligands were conducted at 4, 22, 30, and 37°C for 4 h. After 
quantitation by SDS-PAGE, the most effective coupling condition with the least amount 







As a final optimization, the two ligands were employed at their appropriate pH 
and at room temperature over a timespan of 24 h (Figure 3.13). The results indicate that 
for both conditions, protein degradation begins to become a significant factor after 
approximately 8 h, leading to a subsequent decrease in Glaser-Hay bioconjugation 
efficiency.  
The timecourse experiments also reveal that the conjugations employing 10  
(Figure 3.13, A) result in less overall protein degradation relative to reactions using 2 
(Figure 3.13, B). Research on Glaser-Hay bioconjugations published concurrent with our 
findings found that another 2,2-bipyridyl variant similar to our ligand 10 can trap Cu(II) 
species in a pentacoordinate gel.6 This sequestration prevents the Cu(II) from initiation 
radical oxygen species that are known to cause oxidative damage to proteins.   
Figure 3.12. Effect of 
reaction temperature on 
coupling. Results indicate 
that room temperature 
(22°C, lane 2) affords an 
increase in coupling over 
the previously published 
conditions (lane 1). 
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Figure 3.13. Timecourse data for optimized Glaser-Hay bioconjugations demonstrating 
coupling efficiency (line) in combination with protein degradation (bars).  
A) Timecourse of the Glaser-Hay bioconjugation with ligand 10, pH 8.0.  











































































































This decreased degradation allows for increased reaction times that facilitate 
higher levels of coupling. In the case of 2, lowering the pH to 6.0 appears to accelerate 
the reaction rate, improving coupling prior to degradation.  
Ultimately, we elucidated two optimized conditions that improved coupling 
efficiency and/or minimized protein degradation, resulting in yields of 95% or greater as 
determined by absorbance spectroscopy. For ligand 2, reactions performed at 22°C, pH 
6.0, for 4 h afforded the best results, while 10 functioned best at 22°C, pH 8.0, for 8 h. 
Each of these conditions facilitates substantial improvement over the previously 
published conditions of 2, 4°C, pH 7.4, for 4 h. Selection of appropriate ligand is most 
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likely application dependent, as 2 affords shorter reaction times to obtain the 
bioconjugate, while 10 provides slower couplings, but with less protein degradation.  
In conclusion, two new reaction conditions have been developed towards 
optimizing Glaser-Hay bioconjugations.7 The ability to increase coupling efficiency, 
while simultaneously decrease harmful protein degradation, increases the overall utility 
of this reaction. Expanding the chemical toolbox of bioorthogonal bioconjugations is 
essential towards the preparation of various conjugates having medical and materials 
based applications. The Glaser-Hay reaction in particular is unique in its installation of a 
linear, carbon-carbon covalent bond, which also facilitates secondary reactions from the 
diyne moiety. Either lowering the pH with the traditional TMEDA ligand, or employing a 
carboxylated biphenyl ligand generates more efficient couplings with less degradation 
than the previously reported conditions. 
 
Materials and Methods 
 
 
General: Solvents and reagents were obtained from either Sigma Aldrich or Fischer 
Scientific and used without further purification. Plasmids encoding protein and 
synthetase/tRNA pair were provided by the laboratory of Dr. Peter Schultz at The Scripps 
Research Institute. All proteins were purified according to manufacturer’s protocols using 
a Qiagen Ni-NTA Quik Spin Kit. Reactions were performed in ambient conditions with 
non-distilled solvents. SDS-PAGE gels were imaged on a BioRad Molecular Imager (Gel 
Doc XR+). 
Synthesis of p-propargyloxyphenylalanine (pPrF): Boc-Tyrosine-OMe (114 mg, 2 eq, 
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0.385 mmol) was added to a flame-dried vial. Cesium carbonate (254 mg, 3 eq, 0.578 
mmol) was then added, followed by dry DMF (3 mL). This mixture was stirred at 100 °C 
for 20 mins. 5- Bromo-1-pentyne (20 μL, 1 eq, 0.193 mmol) was then added to the 
mixture, as well as a catalytic potassium iodide. The reaction was stirred overnight at 100 
°C, then cooled to room temperature and washed with brine (10 mL) and diethyl ether 
(10 mL). The ether layer was then washed with brine (10 mL x 3). The brine layer was 
then back-extracted with ether (10 mL). The organic layers were combined, dried with 
magnesium sulfate, filtered, and excess solvent was removed in vacuo. Column 
chromatography (silica gel, 5:1 hexanes/ethyl acetate) was performed to yield the desired 
product as a white crystal (22 mg, 0.061 mmol, 31.6% yield). 1H NMR (400 MHz, 
CDCl3): δ 7.02 (d, J = 12 Hz, 2 H), 6.82 (d, J = 12 Hz, 2 H), 4.95 (d, J = 8 Hz, 1 H), 4.53 
(d, J = 8 Hz, 1 H), 4.03 (t, J = 4 Hz, 2 H), 3.71 (s, 3 H), 3.02 (m, J = 8 Hz, 1 H), 2.39 (t, J 
= 4 Hz, 2 H), 1.97 (m, J = 8 Hz, 2 H), 1.55 (s, 1 H), 1.41 (s, 9 H). 13C NMR (400 MHz, 
CDCl3): δ 172.4, 157.9, 130.3, 127.9, 114.5, 83.5, 79.9, 68.8, 66.0, 54.5, 52.2, 37.4, 
28.3, 28.2, 21.1, 15.1.  
Expression of GFP containing pPrF: A pET-GFP-TAG plasmid (0.5 μL) was co-
transformed with a pEVOL aminoacyl tRNA synthetase plasmid (0.5 μL) into 
Escherichia coli BL21 (DE3) competent cells using an Eppendorf Eporator 
electroporator. The cells were then plated (100 μL) on LB agar supplemented with 
ampicillin (50 μg/mL) and chloramphenicol (34 μg/mL). The plates were incubated 16 
hours at 37°C. One colony was used to inoculate LB media (10 mL) containing 
ampicillin and chloramphenicol. The culture was shaken overnight at 37°C and used to 
initiate an expression culture (250 mL media, ampicillin 50 μg/mL, chloramphenicol 34 
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μg/mL) at an OD600 = 0.1. The cultures were incubated at 37°C until OD600 = 0.6 was 
reached. Protein expression was induced by addition of 20% arabinose (250 μL), 0.8 mM 
isopropyl-β-D-1-thiogalactopyranoside (IPTG; 250 μL), and the unnatural amino acid 
(2.5 mL, 100 mM). Cultures were incubated at 30°C overnight, then pelleted by 
centrifugation (5,000 rpm, 10 min). Pelleted cells were stored at -80°C until purification. 
The cell pellet was resuspended with 500 μL of Bugbuster (Novagen), and 200 μL of cell 
lysis buffer and incubated for 20 minutes at 37°C. Cellular debris was pelleted out by 
centrifugation at 5,000 rpm for 10 minutes and the supernatant was added to an 
equilibrated Ni-NTA resin (200 μL). GFP was purified according to manufacturer’s 
protocol before being analyzed by SDS-PAGE (BioRad 10% precast gels, 150 V, 1.5 
hours). Gels were stained using Coomassie Brilliant Blue, and destained using a destain 
solution (60% deionized H2O, 30% MeOH, 10% acetic acid). The gel was analyzed 
using the Coomassie protocol on the gel imager. Protein was used without further 
purification. 
Biological Glaser-Hay Procedure under Optimized Condition 1: To a sterile 1.5 mL 
eppendorf tube, the following were added: 5 μL of a vigorously shaken solution of CuI 
(500 mM in H2O) and 5 μL of tetramethylethylenediamine (2 in 500 mM in H2O). The 
two solutions were thoroughly mixed by pipetting. Next, 30 μL of GFP containing a 
terminal alkyne UAA at position 151 (GFP151/pPrF; pH = 6, 1.05 mg/mL) and 20 μL of 
AlexaFluor-488 Alkyne (1 mM in DMSO) were added to the tube. The reaction was 
incubated at room temperature (22°C). After 4 hours, excess reactants were removed by 
buffer exchange using Spin-X UF concentrator columns. The reaction was washed with 
PBS (8x200 μL) to a final volume of 50 μL. The reaction was analyzed by SDS-PAGE 
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and imaged using a SYPRO Ruby scan to analyze fluorescence. The gel was stained for 3 
hours using Coomassie Brilliant Blue, then destained overnight using a methanol solution 
(60% deionized H2O, 30% MeOH, 10% acetic acid). The gel was then analyzed on the 
gel imager using a Coomassie scan protocol.  
Biological Glaser-Hay Procedure under Optimized Condition 2: To a sterile 1.5 mL 
eppendorf tube, the following were added: 5 μL of a vigorously shaken solution of CuI 
(500 mM in H2O) and 5 μL of 2,2’-Bipyridine-4,4’-dicarboxylic acid (10, 500 mM in 1 
M NaOH). The two solutions were thoroughly mixed by pipetting until a dark brown 
color was achieved. Next, 30 μL of GFP containing a terminal alkyne UAA at position 
151 (GFP151/pPrF; pH = 8, 1.05 mg/mL) and 20 μL of AlexaFluor-488 Alkyne (1 mM 
in DMSO) were added to the tube. The reaction was incubated at room temperature 
(22°C). After 8 hours, excess reactants were removed by buffer exchange using Spin-X 
UF concentrator columns. The reaction was washed with PBS (8x200 μL) to a final 
volume of 50 μL. The reaction was analyzed by SDS-PAGE and imaged using a SYPRO 
Ruby scan to analyze fluorescence. The gel was stained for 3 hours using Coomassie 
Brilliant Blue, then destained overnight using a methanol solution (60% deionized H2O, 
30% MeOH, 10% acetic acid). The gel was then analyzed on the gel imager using a 
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CHAPTER 4: TOWARDS THE PREPARATION OF MULTIVALENT 
BIOCONJUGATES 
Introduction 
 While bioconjugates are powerful tools with various applications in medicine, 
materials, and pharmaceuticals, they traditionally consist of only two reaction partners.1 
The most commonly employed methods of creating bioorthogonal conjugates, which 
include azide-alkyne “click” reactions, Staudinger ligations, and metal-catalyzed cross 
coupling reactions, primarily result in divalent conjugates.2, 3 The resulting complex is 
thus limited to only two functions, such as localization and therapeutic intervention, or 
enzymatic catalysis and visualization. Preparing a multivalent conjugate consisting of 
three or more biomolecules, small molecules, or probes, would expand the utility of 
bioconjugates in the fields of medicine and materials. For example, an antibody—drug 
conjugate could be further functionalized with a fluorescent tracking molecule to 
accomplish localization, therapeutic intervention, and visualization all in one complex.  
 For bioconjugation reactions involving proteins, unnatural amino acid 
conjugations have already been established as superior to conjugation of a protein’s 
natural 20 amino acids in the preparation of several bivalent conjugates. This is due to the 
lack of selectivity as multiple residues of each amino acid occur in proteins, resulting in 
multiple, conjugation sites within a protein. Therefore, producing a multivalent conjugate 
using unnatural amino acid would be favorable to other methods, as UAA conjugation 
enables a high degree of selectivity over the location of conjugation and avoids 
production of a heterogeneous product mixture.   
 Optimization of existing unnatural amino acid technology towards the generation 
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Figure 4.1. A)	  


































1. nAF, pH 4.5,
37° C, 5 days
2. Alexa Fluor® 488
pH 7.0, 37 °C, 24 hour
anti-Her2-IgG-pAcF/AzK anti-Her2-IgG-nAF/488
multivalent conjugates by incorporation of multiple amino acids has already been 
reported in the literature.4-6 Notably, in 2010, Wan et. al incorporated two different UAAs 
into GFP by simultaneous suppression of both the amber (TAG) and ochre (TAA) stop 
codons using two distinct orthogonal amino-acyl (aaRS)/tRNA pairs in E. coli.4 Xiao et. 
al developed this methodology further to incorporate multiple UAAs into a protein in 
mammalian cells, which was utilized to generate a multivalent conjugate as well.5 Using 
an orthogonal pyrrolysyl aaRS/tRNA pair to suppress the TAA codon alongside a tyrosyl 
aaRS/tRNA pair to suppress TAG, UAAs pAcF (Figure 4.1, A) and AzK (Figure 4.1, A) 
were incorporated into a full-length anti-HER2 antibody. The drug auristatin (nAF) was 
conjugated to pAcF while the cyclooctyne fluorophore AlexaFluor 488 sDIBO was 











 In 2010, Neumann et. al evolved a quadruplet-decoding ribosome that would 
recognize and incorporate UAAs in response to quadruplet codons.6 Using this 
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technology, Neumann genetically encoded an azide and alkyne into calmodulin and 
performed an internal Cu(I)-catalyzed cycloaddition reaction (Figure 4.2).  
 
 
While these researchers have made advancements towards, and, in the case of Xiao, even 
generated multivalent conjugates, suppressing multiple codons with multiple evolved 
orthogonal synthetases or evolving a novel ribosome can be tedious and complicated. If, 
instead of incorporating multiple UAAs, a single UAA 
could be incorporated with the potential to undergo two 
bioconjugation reactions, a multivalent conjugation could 
be performed without the need for complicated protocols 
involving genomic insertion of unnatural amino acids. 
The end result would be a complex with three 
functional biomolecules conjugated at a single location 
(Figure 4.3).  
 The end result of an “click” cycloaddition reaction between an azide and a 
terminal alkyne, one of the most widely used bioorthogonal conjugation methods, is a 
stable triazole that is nearly impossible to cleave, reduce, or oxidize; therefore, triazoles 
have little potential to be reacted further to increase the valence of a bioconjugate.7 





Figure 4.3. Multivalent conjugate 
consisting of a therapeutic peptide 
(red), an antibody (blue), and a 
fluorescent probe (yellow) with 
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reactive center multivalent conjugate
reactions, an internal 1,3-diyne, can be used as an electron-rich center for additional 
conjugation reactions (Figure 4.4). Therefore, we aim to develop a reliable method to 
further functionalize the divalent biomolecules produced from these two coupling 




Many known reactions have been reported between a 1,3-diyne and substituted 
azides, amines, thiols, tetrazines, nitriles, and silyls.8-14 However, most of these reactions 
were performed under synthetic organic conditions  (organic solvents, high temperatures, 
etc.) and have yet to be accomplished between biomolecules in a physiological setting. 
Thus, we aim to translate these organic reactions to a biological context in the pursuit of 
multivalent, multifunctional bioconjugates that can be detected by SDS-PAGE, mass 
spectrometry, or fluorimetric analysis. Toward this end, initial efforts focus on the 
creation of detectable homodimeric protein complexes and heterodimeric complexes of 
proteins, DNA oligonucleotides, PEG molecules and fluorophores. Additional reactions 
will then be investigated as a means of conjugating a third reaction partner to a divalent 
complex in order to create a multivalent bioconjugate with a single point of attachment.  
 
 
Figure 4.4. A divalent conjugate harboring an internal 1,3-diyne could be reacted further to create 
a multivalent conjugate. 
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Results and Discussion 
Dimer Preparation 
 In order to create multivalent biomolecules consisting of three or more reaction 
partners, we first sought to expand our library of dimers beyond the protein-fluorophore 
conjugate we previously reported via Glaser-Hay and Cadiot-Chodkiewicz reactions.15, 16 
The creation of an internal 1, 3-diyne is key for downstream addition reactions yielding a 
multivalent conjugate. Initial efforts centered on generating protein-protein dimers via the 
Glaser-Hay reaction with the end goal of adding a small molecule such as a fluorophore 
as the third component of the complex. The results of all Glaser-Hay dimer reactions are 











 All reactions were performed at 4°C and for 4 hours using CuI and TMEDA as 
catalysts unless otherwise explicitly stated. Given our success using GFP for previous 
Glaser-Hay bioconjugations, we decided to first employ this protein towards the 
Table 4.1. Glaser-Hay reactions. 




































formation of protein homodimers with the alkynyl UAA pPrF (Figure 4.5) inserted at 
position 151 (Table 1, Entry 1). This reaction was unsuccessful as indicated by SDS-
PAGE, potentially due to the steric bulk of the proteins, which may have prevented them 
from coming in close enough proximity for reaction. We thus employed terminal alkyne 
linkers (Figure 4.5, 1-4) of varying lengths to increase the distance between the proteins 











 With no positive results, we tried different sites on GFP at which the UAA could 
be inserted and reacted to form homodimers. Reactions were attempted with pPrF at 
position 3 and 133, with and without linker 1 present (Table 1, Entries 6-9), but no 
positive results were achieved. Given our recent Glaser-Hay optimization results (see 
Chapter 2), we reasoned that employing the ligand 2,2’-bipyridine-4,4’-dicarboxylic acid 
(5) might achieve better coupling. Because this ligand was found to limit protein 
degradation in previous experiments, reactions using 5 were performed for 16 hours 
Figure 4.5. Structures of A) alkyne linkers; B) bidentate nitrogenous ligands; C) 
brominated alkyne linkers; and D) unnatural amino acids employed in dimerization 
reactions.  
	   53 
Table 4.2. Cadiot-Chodkiewicz reactions. The notation “-“ indicates no 
dimer formation, while “+/-“ indicates a successful dimer experiment that 
was difficult to replicate. 
(Table 1, Entries 10-13). Despite increased reaction time with ligand 5, no significant 
dimerization was achieved. Lastly, under Glaser-Hay conditions, a 15-mer single 
stranded DNA oligonucleotide with a 5’-hexynyl modification and a 5 kDa alkyne PEG 
molecule were reacted with GFP151/pPrF; however, SDS-PAGE indicated no 
bioconjugation (Table 1, Entries 14-15).  
 Dimers generated via the Cadiot-Chodkiewicz reaction of a terminal alkyne and 
bromoalkyne were next explored. In the previous Glaser-Hay reactions between proteins 
involving alkynyl linkers, it is possible that the cross coupling of two linkers was favored 













We reasoned that using Cadiot-Chodkiewicz conditions with brominated reaction 
partners might limit unwanted polymerization of linkers. The results and conditions of all 
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Cadiot-Chodkiewicz reactions are displayed in Table 2. All reactions were performed at 
4°C for 4 hours using CuI and TEA as catalysts unless explicitly stated otherwise. 
 First, green fluorescent protein harboring brominated alkyne pBrPrF (Figure 4.5, 
D) at 151 was reacted with linkers 1 and 3, but no dimer was formed (Table 2, Entry 1-2). 
The aromatic brominated UAA variant pBrEtF was also employed with linker 1 towards 
the formation of homodimer, yet no promising results were achieved (Table 2, Entry 3). 
We hypothesized that, although TMEDA was not present, some undesired terminal 
alkyne coupling of the linkers might have still occurred in the presence of Cadiot-
Chodkiewicz catalysts TEA and CuI. In an effort to completely eliminated off-site 
coupling and encourage protein dimerization, we prepared brominated alkyne linkers 
(Figure 4.5, 6-7) according to the same bromination protocol used to prepare brominated 
UAAs.17 Homodimer reactions involving GFP151/pPrF, GFP133/pPrF, and GFP3/pPrF 
using various brominated linkers were attempted, with no positive results (Table 2, 
Entries 4-8). Recent literature reported the effect of changing the base in the Cadiot-
Chodkiewicz reaction and indicated that cyclic secondary amines increased the yield 5-
fold over tertiary amines like TEA.18, 19 Thus, pyrrolidine was substituted for TEA in two 
additional reactions, but no increase in dimer yield resulted (Table 2, Entries 9-10).   
 We hypothesized that homodimers of GFP may be hard to achieve due to 
electronic repulsion of identical surface potentials between proteins. Thus, we tried to 
form heterodimers of GFP by performing reactions between proteins with UAAs at 
differing positions. Attempts were made to conjugate proteins directly or indirectly with a 
brominated linker (Table 2, Entries 11-18). Some formation of heterodimer was detected 
via SDS-PAGE when GFP151/pBrPrF was reacted directly with GFP133/pPrF (Figure 
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4.6, Lane 3). However, this result was difficult 
to reproduce, and attempts to further optimize 
this reaction using pyrrolidine as the base or 
using the aromatic pBrEtF as the brominated 
UAA did not result in an increase in yield 
(Table 2, Entries 17-18). Additionally, the 
alkynyl DNA oligonucleotide was tested as a 
potential reaction partner for GFP151/pBrPrF, 
but no heterodimer was reported (Table 2, 
Entry 19). We hypothesized that, in addition 
to steric effects influencing dimerization, relative protein and/or linker concentrations 
may be an important factor as well. In a final attempt to generate a protein dimer, a more 
concentrated GFP151/pBrPrF sample was reacted under Cadiot- Chodkiewicz conditions 
with and without 1 μL undiluted linker 1 
(Table 2, Entries 20-21). Analysis by SDS-
PAGE revealed moderate dimerization when 
linker 1 was present (Figure 4.7, Lane 1). 
Lane 2 also showed a slight band indicating a 
dimer that theoretically should not form, given 
that both reaction partners are brominated and 
no linker was present. Therefore, this band may indicate a slight impurity in the sample, 
but the differential staining between lanes 1 and 2 still validates dimer formation in lane 










Figure 4.6. SDS-PAGE analysis of Cadiot-
Chodkiewicz dimer reactions corresponding 
to entries 14-15 in Table 2. 
Figure	  4.7. SDS-PAGE analysis of Cadiot-
Chodkiewicz dimer reactions corresponding 
to entries 21-21 in Table 2. 
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generating protein dimers using more concentrated protein and linker reagents.  
 Since alkyne coupling reactions involving the small molecule fluorophore and 
GFP have been successful under both Glaser-Hay and Cadiot-Chodkiewicz conditions, 
we hypothesized that the unsuccessful reactions involving GFP as both reaction partners 
was largely due to steric hindrance that is difficult to overcome even with linkers. Thus, 
we investigated the 8.5 kDa protein ubiquitin (Ub) with an unnatural amino acid inserted 
at position 48 as a potential reaction partner. We reasoned that reacting a smaller protein 
with the larger GFP might solve the issue of sterics. Ubiquitination is also a common 
post-translational modification, suggesting that this heterodimeric species should be 
accessible.20 An unnatural amino acid bearing an azide (pAzF) was incorporated into 
ubiquitin at site 48 with the intention of performing a Cu(I)-catalyzed azide alkyne 
cycloaddition (CuAAC) reaction. Because the product of a CuAAC is a very stable 
triazole rather than a diyne, we did not intend to use the protein product for downstream 
multivalent reactions, but rather to test ubiquitin as a potential solution to the steric 
problem. Table 3 shows all CuAAC reactions, which were performed for 16 hours at 4°C. 
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Table 4.3. CuAAC reactions. The notation “-“ indicates no dimer formation, “+” indicates a 
positive, replicated experiment, and “+/-“ indicates a successful dimer experiment that was 








 Lastly, we investigated a reaction between a bromoalkyne and an azide to yield a 
bromotriazole functionality.21 Though a triazole functional group is stable and generally 
unreactive, a bromotriazole is a potential starting point for a Sonogashira reaction 
between an alkyne and an aromatic halide. The literature reports an organic coupling 
reaction between an alkyne and a halotriazole, but this specific reaction has not been 
accomplished with biomolecules under 
physiological conditions.22 Through this 
reaction, a trivalent conjugate could be 
achieved without having to generate the 
diyne. Reacting the bromoalkynyl protein 
GFP151/pBrPrF with an AlexaFluor 488 
Azide fluorophore resulted in fluorescent 
protein when analyzed by SDS-PAGE 
(Figure 4.8, Lane 1), which indicated a 
successful reaction. Employing 
GFP151/pBrEtF in the reaction also worked well to achieve a fluorescent signal (Figure 




Figure 4.8. SDS-PAGE analysis of 
bromotriazole-furnishing CuAAC reactions 
corresponding to entries 6-8 in Table 3.  




















Figure 4.9. Reactions employed towards the generation multivalent bioconjugates using A) an 
internal 1,3-diyne or B) a bromotriazole as the starting point. 
4.8, Lane 2). The aromatic UAA variant pBrEtF displayed a greater rate of coupling, as 
less protein was detected by Coomassie staining, yet a brighter fluorescent signal was 
observed relative to the pBrPrF UAA. Reacting GFP151/pAzF with GFP151/pPrBrF 
appeared to yield a small amount of dimer, though this amount would not be sufficient 
for downstream multivalent reactions (Figure 4.8, Lane 3). 
Multivalent Conjugates 
 Though we found no suitable method of creating a protein-protein dimer in high 
yield throughout many trials, we nevertheless explored several reactions that had the 
potential to generate multivalent bioconjugates. Our experiments centered around five 
reactions reported in the literature: a pyrrole-forming reaction of a diyne and primary 
amine (Figure 4.9, A, c) 23, 24, a thiol-yne reaction between an alkyne and thiol (Figure 4.9, 
A, d)11, a 1,3-dipolar cycloaddition and carbocyclization of an azide and diyne to form a 
naphthotriazole (Figure 4.9, A, c)13, a tetrazine ligation (Figure 4.9, A, a)14, and a 
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 Before employing these reactions in a biological context, we performed reactions 
on organic compounds to first validate the procedures found in the literature and then to 
find optimized conditions that would be compatible with biological macromolecules. To 
first accomplish the reactions in an organic context, we 
prepared an organic solvent-soluble dimer of 
phenylacetylene, 1,4-diphenylbuta-1,3-diyne, (Figure 4.10, 
9) and a water-soluble dimer of propargyl alcohol, hexa-
2,4-diyne-1,6-diol, (Figure 4.10, 8) using Glaser-Hay 
reaction conditions.  
 We first attempted the synthesis of a substituted pyrrole by 9 with aniline in 
DMSO with added KOH at 80°C for 4 hours, but no pyrrole product was isolated. The 
reaction was repeated again under more biologically compatible conditions—for 16 hours 
at room temperature—but no product was identified by NMR spectroscopy. The literature 
reports a Cu(I) catalyzed cycloaddition of diynes with a primary amine, so we again 
repeated the reaction with the addition of CuI at 50°C degrees for 24 hours, and then at 
90°C for another 24 hours.24 Although the fully cyclized product was not isolated, peaks 
in the alkene region of the NMR spectrum indicated a possible single or double addition 
of the primary amine to the alkyne and conversion of the alkyne to an alkene. A similar 
result was found upon reacting aniline with 8. Based on these promising results, we 
employed the reaction in a biological setting and reacted a 14-base DNA oligonucleotide 
with a 3’ primary amine terminus modification with a protein-fluorophore dimer 
consisting of GFP151/pPrF and AlexaFluor 488 Alkyne conjugated via a diyne 
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PAGE, but the protein-fluorophore dimer exhibited no noticeable shift in molecular 
weight compared to a control experiment, indicating a failure of the DNA amine 
oligonucleotide to add to the triple bonds.  
 A 1,3-dipolar coupling of a 
1,3-diyne and azide was next 
explored. The complete reaction of 
a 1,3-diyne and an azide involves 
the cycloaddition of the azide 
across the triple bond followed by 
a carbocyclization yielding a 
naphthotriazole.  The reaction was 
first attempted between organic compounds and then in a biological context to create a 
trivalent biomolecule. Benzyl azide was added to 9 and stirred at 90°C for 2 days with 
CuI as a catalyst. Gratifyingly, two products were isolated and their structures confirmed 
by 1H NMR: a fully cyclized naphthotriazole (Figure 4.11, 11) and a triazole that had yet 
to undergo carbocyclization (Figure 4.11, 10). The cycloaddition of benzyl azide in both 
products was confirmed by a shift of the methylene hydrogens’ (green) signal from δ 
4.39 ppm in benzyl azide to around δ 5.6 in both 10 and 11. Although this complete 
reaction required a high temperature and a long reaction time, which would limit its 
application to a biological reaction, we hypothesized that the non-carbocyclized product 
may form under reduced time and temperature conditions. A non-carbocyclized molecule 
in this case would still constitute a multivalent product and validate this methodology as a 
means of generating multivalent bioconjugates.  
Figure 4.11. Structures of non-carbocyclized (10) and 
carbocyclized (11) products from reaction of benzyl 
azide with 9. The red carbon atoms indicate the atoms 
that participate in carbocyclization. These products were 
confirmed by 1H NMR. The downfield shift of the 
methylene hydrogens’ (green) signal indicated 
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 A 1,3-diyne heterodimer of GFP151/pPrF and AlexaFluor 488 Alkyne was 
reacted with a 5 kDa azide PEG at 4°C for 14 hours using CuSO4, TBTA, and TCEP as 
catalysts. A successful reaction would be confirmed by a shift in molecular weight of the 
complex as determined by SDS-PAGE. Unfortunately, no such product was achieved. 
We repeated an identical reaction with the temperature increased to 37°C, but no 
trimerization was identified, potentially due to the temperature and steric limitations of 
the reaction. Further optimization with different reactants is necessary as the PEG-azide 
has generally not worked well in any bioconjugation in our laboratory.  
 The tetrazine ligation, which proceeds quickly and 
efficiently without the need for an energy-lowering catalyst, 
was next explored. The high fidelity of the uncatalyzed 
tetrazine ligation is due to the strained alkene moiety with 
which the tetrazine reacts, but we reasoned that this 
reaction might proceed with the more electron-rich 1,3-
butadiyne functionality we hoped to employ. Diyne 8 was 
reacted with 3,6-diphenyl-1,2,4,5-tetrazine (Figure 4.12, A) 
for 16 hours at room temperature, but the desired product was not isolated or confirmed 
by NMR, which likely indicates that the diyne is not a sufficient reaction partner for an 
uncatalyzed ligation reaction. Nevertheless, we tried the reaction biologically, between 
3,6-di-2-pyridyl-1,2,4,5-tetrazine (Figure 4.12, B) and GFP151/pPrF, with the hope that 
the highly conjugated product would display a fluorescence emission spectrum different 
from that of unconjugated GFP/pPrF. The reaction was incubated at room temperature for 









Figure 4.12. Structures of 
tetrazines employed in 
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there was no shift in the fluorescence emission curve compared to unreacted 
GFP151/pPrF.  
 The successful 1,3-dipolar azide-bromoalkyne cycloaddition yielding a divalent 
molecule with a bromotriazole functional group led us to attempt a Sonogashira reaction 
to generate a trivalent bioconjugate. A bromotriazole-containing dimer of 
GFP151/pBrPrF and AlexaFluor 488 Azide was added to a DNA oligonucleotide bearing 
a hexynyl modification, followed by premixed catalytic CuI, DIPEA, and PdCl2(PPh3)2. 
The mixture was incubated for 4 hours at room temperature and analyzed via SDS-
PAGE; however, no noticeable gel shift, indicating Sonogashira coupling, was observed. 
The same reaction was repeated with a 5 kDa PEG alkyne as the reaction partner, but 
again no trimerization was detected. We next tried more biologically compatible catalytic 
conditions, consisting of Pd(OAc)2, TPPTS, and CuOTf, found in the literature.25 The 
alkynyl DNA, alkynyl PEG, and alkynyl protein GFP151/pPrF were both used as the 
third reaction partner in separate reactions for 1 hour at room temperature. Unfortunately, 
analysis by SDS-PAGE did not confirm any positive results.  
 Finally, we turned to the thiol-yne reaction between an alkyne and thiol, which 
has previously been accomplished using a catalytic photoinitator, which emits reactive 
species to drive the reaction upon irradiation with UV light.11 Because this thiol addition 
reaction only requires one pi bond for addition to occur, the presence of 4 pi bonds in our 
1,3-diyne substrate would allow for anywhere between 1 and 4 thiol molecules to add to 
the complex. Although this reaction is in theory less specific than other conjugation 
methods described here, the resulting product would still constitute a viable multivalent 
product.  An organic reaction between 4-methoxybenzenethiol and 9 was first tested 
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using photoinitiator 2,2-dimethoxy-2-phenylacetophenone (DPAP) and UV irradiation at 
365 nm. Analysis by NMR spectroscopy showed shifts in the aromatic region of the 
spectrum, indicating some degree of thiol addition to the triple bonds.  
 The reaction was transitioned to a biological environment, where a 14-mer DNA 
olignucleotide with a 3’ thiol modification was added the diyne dimer GFP151/pPrF—
AlexaFluor 488 Alkyne and subjected to two rounds of irradiation at 365 nm for 10 
minutes followed by 2 hours of incubation at 4°C. Analysis by SDS-PAGE indicated no 
successful reaction and significant protein degradation, likely due to excess radicals 
generated from the photoinitiator. The reaction was then repeated with two rounds of 
irradiation for 5 minutes followed by 1 hour of incubation at 4°C, but degradation was 
still observed. Thus, the reaction was performed again with one round of irradiation for 5 
minutes and 45 minutes of incubation, and although less protein degradation occurred, no 
thiol addition was observed. The lack of successful addition could mean that the complex 
is too sterically hindered for addition to occur, as was potentially the case with the 
dimerization experiments.   
 To test whether a smaller thiol 
reaction partner could be employed to 
overcome the steric limitations, a 
fluorescent dansyl-glutathione (dGSH, 
Figure 4.13) complex was reacted with 
unconjugated GFP151/pPrF using a more specific protocol for an analogous biological 
reaction between a thiol and an alkene. 26 A fluorescent band on SDS-PAGE in the 
+DPAP reaction and lack of signal in the –DPAP reaction indicated a successful thiol-
Figure 4.13. Structure of fluorescent molecule 
dansyl-glutathione (dGSH) employed in thiol-yne 
reactions. 
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yne reaction between dGSH and alkyne GFP (Figure 4.14). The reaction was extended to 
an alkyne-derivatized Sepharose resin, which fluoresced when the thiol fluorophore was 
added in the presence of photoinitiator DPAP, but did not fluoresce when in the absence 










 Since this reaction was not performed on a divalent molecule, but rather on an 
unconjugated protein, the multivalent product was not achieved in full. However, this 
result supports the hypothesis that the size of the third reaction partner plays an important 
role in whether the reaction is successful. Additionally, this thiol-yne reaction can be 
easily employed towards a multivalent product whenever a protein and non-fluorophore 
dimer is available and detectable by SDS-PAGE.  
 In conclusion, many approaches were explored towards the generation of divalent 
and multivalent bioconjugates. Reactions to form protein homodimers and heterodimers 
of proteins, fluorophores, DNA oligonucleotides, and PEG molecules were performed 
under Glaser-Hay, Cadiot-Chodkiewicz, and CuAAC reaction conditions. While little 
1agfd
A B1 2L
Figure 4.15. Reactions between 
alkynyl Sepharose resin and 
dGSH after washing with PBS 
in the A) presence of DPAP and 
B) absence of DPAP.  Figure 4.14. Fluorescent (top) 
and Coomassie (bottom) stained 
gels of thiol-yne reaction 
between GFP 151/pPrF and 
dGSH fluorophore. 
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success was achieved with the Glaser-Hay reactions, two protein dimers were detected 
under Cadiot-Chodkiewicz conditions but were unfortunately hard to replicate. These 
results provide evidence that the reactions are largely influenced by the steric bulk of the 
reaction partners and relative concentration of the proteins and linkers. The CuAAC 
reactions also yielded no dimeric protein complexes, but CuAAC reactions between a 
bromoalkyne and an azide were successfully employed to form a GFP—fluorophore 
complex harboring an internal bromotriazole functional group. 
 Of the five reactions employed toward the creation of multivalent products, the 
thiol-yne reaction showed the most promise. Addition of a thiol-containing dansyl-
glutathione fluorophore to both alkyne GFP and alkyne-derivatized Sepharose resin was 
successfully performed using a photocatalyst. While the azide-diyne cycloaddition 
reaction was carried out successfully in an organic context, the reaction did not proceed 
under biological conditions. Further optimization of concentrations and reaction 
conditions, in addition to screening and selection of appropriate reaction partners, will be 
key in successfully achieving multivalent bioconjugates using this methodology 
 
Materials and Methods 
 
General: General solvents and reagents, including the AlexaFluor 488 Alkyne and 
Azide, were obtained from Sigma Aldrich, Acros Organics, or Alfa Aesar and used 
without further purification. Plasmids were provided by the laboratory of Dr. Peter 
Schultz at The Scripps Research Institute, as well as by the laboratory of Dr. Ashton 
Cropp at Virginia Commonwealth University. The dGSH molecule was provided by the 
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laboratory of Dr. Lisa Landino at William & Mary. Reactions were conducted under 
ambient atmosphere with solvents directly from the manufacturer without further 
purification. All proteins were purified according to manufacturer’s protocols using a 
Qiagen Ni-NTA Quik Spin Kit. Unless indicated otherwise, all solutions were prepared in 
deionized water (pH ~ 7). SDS-PAGE gels were imaged on a BioRad Molecular Imager 
(Gel Doc XR+). All NMRs were acquired on an Agilent Technologies 400 MHz NMR.  
 
Synthesis of 6: 1,5-Hexadiyne (0.100 g, 1.28 mmol) was added to a vial containing 
AgNO3 (0.043 mg, 0.26 mmol) and N-bromosuccinamide (NBS, 0.50 g, 2.82 mmol) in 
acetone (8 mL). The mixture was allowed to stir for 2 hours at room temperature, after 
which it was diluted with hexanes (15 mL) and the resulting crystals were filtered. The 
filtrate was then evaporated under reduced pressure and filtered through a silica plug 
using hexanes as eluent. Excess eluent was removed under reduced pressure again to 
yield the desired product as a brown oil (0.140 g, 0.593 mmol, 46% yield). 1H NMR (400 
MHz, CDCl3): δ 2.43 (s, 4H) ppm. 
 
Synthesis of 7: 1,9-Decadiyne (0.15 g, 1.12 mmol) was added to a vial containing 
AgNO3 (0.038 mg, .22 mmol) and N-bromosuccinamide (NBS, 0.48 g, 2.46 mmol) in 
acetone (8 mL). The mixture was allowed to stir for 2 hours at room temperature, after 
which it was diluted with hexanes (15 mL) and the resulting crystals were filtered off. 
The filtrate was then evaporated under reduced pressure and filtered through a silica plug 
using hexanes as eluent. Excess eluent was removed under reduced pressure again to 
yield the desired product as a clear oil (0.327 g, 1.12 mmol, 100% yield). 1H NMR (400 
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MHz, CDCl3): δ 2.18 (t, 4H), 1.55-1.29 (m, 8H) ppm. 
 
Synthesis of 8: Propargyl alcohol (2.05 g, 36.54 mmol, 2.11 mL) was added to THF (24 
mL) in a flame dried round-bottom flask. Copper iodide (160 mg) was dissolved in 
TMEDA (240 μL) and THF (8 mL). This mixture was then combined with the propargyl 
alcohol and stirred for 48 h while bubbling air through at 60 ̊C. The reaction was then 
purified via column chromatography starting with a mixture of 1:3 Hexanes: Ethyl 
Acetate and ending with a 1:1 mixture of Hexanes: Ethyl Acetate. 1H NMR (400 MHz, 
D2O): δ 4.19 (s, 4H) ppm. 
 
Synthesis of 9: Phenylacetylene (2.00 g, 19.58 mmol, 2.15 mL) was added to THF (24 
mL) in a flame dried round-bottom flask. Copper iodide (160 mg) was dissolved in 
TMEDA (240 μL) and THF (8 mL). This mixture was then combined with the 
phenylacetylene and stirred overnight (16 h) at 60 ̊C. The reaction was then analyzed by 
Thin Layer Chromatography (TLC) in Hexanes and extracted in DCM and brine, and 
excess solvent was removed in vacuo to yield a yellowish solid. 1H NMR (400 MHz, 
CDCl3): 7.56 (d, 4H), 7.42-7.30 (m, 6H). 
 
Synthesis of 10 and 11: To a stirring solution of 1,4-diphenylbuta-1,3-diyne (0.02 g, 
0.098 mmol) in 1 mL acetonitrile, benzyl azide (0.033 g, 0.25 mmol) was added. Next, 
CuI (0.002 g, 0.009 mmol) was added at ambient temperature. The mixture was stirred 
for 5 minutes and then heated to 90°C under an argon atmosphere for 2 days. The 
reaction was checked for completion using TLC, and then cooled to room temperature. 

















The reaction mixture filtered through a pad of celite and then subjected to silica column 
chromatography using 10:1 hexanes:ethyl acetate as the eluent. The carbocyclized 
product (11) was isolated and confirmed by 1H NMR. 1H NMR (400 MHz, CDCl3): δ 









The non-carbocyclized product (10) was also isolated and confirmed by 1H NMR. 1H 
NMR (400 MHz, CDCl3): δ 7.50-7.40 (m, 8H), 7.32-7.26 (m, 5H), 7.12-7.07 (m, 2H), 









Figure 4.16. 1H 
NMR spectrum of 
11. C corresponds to 
solvent peak CDCl3. 
Unlabeled peaks 
between 7 and 8 
ppm correspond to 
remaining aromatic 
hydrogen atoms. 
Figure 4.17. 1H 
NMR spectrum of 
10. B corresponds to 
solvent peak CDCl3. 
Unlabeled peaks 
between 7 and 8 
ppm correspond to 
remaining aromatic 
hydrogen atoms.  
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Organic Thiol-yne Reaction: In an eppendorf tube, 1,4-diphenylbuta-1,3-diyne (9, 0.02 
g, 0.098 mmol) was dissolved in 1 mL DCM. Methoxybenzenethiol (1.14 g/mL, 60 μL, 
0.49 mmol) was added to the tube. The solution was added to a separate tube containing 
2,2-dimethoxy-2-phenylacetophenone (DPAP, 0.003 g, 0.01 mmol). The reaction was 
irradiated at 365 nm for 1 hour and analyzed by TLC, and then irradiated an additional 
hour at 365 nm. The reaction was then extracted 3 times with ethyl acetate and washed 
once with brine. The organic layer was collected, dried with MgSO4, filtered, and excess 
solvent was removed in vacuo. The reaction was subjected to silica column 
chromatography using 10:1 hexanes:ethyl acetate as the eluent, and the isolated product 
was analyzed via 1H NMR. Although no singly definitive structure was identified, shifts 
in the aromatic region of the spectrum indicated likely addition of methoxybenzenethiol 
to 9. 
 
Organic Pyrrole-forming Reaction: In a vial, 1,4-diphenylbuta-1,3-diyne (9, 0.03 g, 
0.15 mmol) was dissolved in 1 mL THF. Aniline (0.14 g, 1.50 mmol, 138 μL) was added, 
followed by copper iodide (0.003 g, 0.015 mmol). The mixture was stirred at 50°C for 24 
hours, then the temperature was increased to 90°C for another 24 hours. Brine and DCM 
were added to the solution, and the reaction was extracted 3 times with DCM and washed 
once with brine. The organic layer was collected, dried with MgSO4, filtered, and excess 
solvent was removed in vacuo. The product was subjected to silica column 
chromatography using 3:1 hexanes:ethyl acetate as the eluent. The isolated fractions were 
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then analyzed by 1H NMR. Although no definitive single product was isolated, new 
doublet peaks in the alkene region of the spectrum indicated that aniline might have 
added to the triple bond, reducing it from an alkyne to an alkene.  
 
Organic Tetrazine Ligation: To a vial containing 5 mL methanol, 3,6-diphenyl-1,2,4,5-
tetrazine (0.095g, 0.41 mmol) was added followed by 8 (0.03 g, 0.27 mmol). The solution 
was stirred at room temperature for 16 hours and incubated (without stirring) at room 
temperature for another 48 hours. The solution was analyzed by TLC to check for 
reaction completion, and the solvent was removed in vacuo. The crude product was 
analyzed by 1H NMR, but no ligated product was identified. 
 
Expression of Protein Containing Unnatural Amino Acid: A pET-GFP-TAG plasmid 
(0.5 μL, for GFP synthesis) or a pET-Ub-TAG plasmid (0.5 μL, for ubiquitin synthesis) 
was co-transformed with a pEVOL aminoacyl tRNA synthetase plasmid (0.5 μL) into 
Escherichia coli BL21 (DE3) competent cells using an Eppendorf Eporator 
electroporator. The cells were then plated (100 μL) on LB agar supplemented with 
ampicillin (50 μg/mL) and chloramphenicol (34 μg/mL). The plates were incubated 16 
hours at 37°C. One colony was used to inoculate LB media (10 mL) containing 
ampicillin and chloramphenicol. The culture was shaken overnight at 37°C and used to 
initiate an expression culture (250 mL media, ampicillin 50 μg/mL, chloramphenicol 34 
μg/mL) at an OD600 = 0.1. The cultures were incubated at 37°C until OD600 = 0.6 was 
reached. Protein expression was induced by addition of 20% arabinose (250 μL), 0.8 mM 
isopropyl-β-D-1-thiogalactopyranoside (IPTG, 250 μL), and the unnatural amino acid 
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(2.5 mL, 100 mM). Cultures were incubated at 30°C overnight, then pelleted by 
centrifugation (5,000 rpm, 10 min). Pelleted cells were stored at -80°C until purification. 
The cell pellet was resuspended with 500 μL of Bugbuster (Novagen), and 200 μL of cell 
lysis buffer and incubated for 20 minutes at 37°C. Cellular debris was pelleted out by 
centrifugation at 5,000 rpm for 10 minutes and the supernatant was added to an 
equilibrated Ni-NTA resin (200 μL). GFP was purified according to manufacturer’s 
protocol before being analyzed by SDS-PAGE (BioRad 10% precast gels, 150 V, 1.5 
hours). Gels were stained using Coomassie Brilliant Blue, and destained (60% H2O, 30% 
MeOH, 10% acetic acid). The gel was analyzed using the Coomassie protocol on the gel 
imager. Protein was used without further purification. 
 
General Procedure for Biological Glaser-Hay Coupling: To a sterile 1.5 mL 
eppendorf tube, the following were added: 5 μL of a vigorously shaken solution of CuI 
(500 mM in H2O) and 5 μL of bidentate nitrogenous ligand (TMEDA or ligand 5, 500 
mM in H2O). The two solutions were thoroughly mixed by pipetting. Next, reaction 
partners 1 and 2 were added to the mixture and mixed by pipetting. Reaction partners 
consisted of GFP/pPrF (20 μL, ~1 mg/mL in PBS), alkyne DNA oligonucleotide (15 μL, 
100 μM in H2O), or alkyne PEG (10 μL, 10 mM in DMSO). In reactions involving 
linkers, 5 μL  of 100 μM linker dissolved in DMSO was added. The reaction was 
incubated at 4°C for 4 hours, unless otherwise stated in the main text. The reaction was 
stopped either by performing SDS-PAGE immediately or by removing excess reactants 
via buffer exchange using Spin-X UF concentrator columns, and then subsequently 
analyzing the purified products by SDS-PAGE.   
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General Procedure for Biological Cadiot-Chodkiewicz Coupling: To a sterile 1.5 mL 
eppendorf tube, the following were added: 5 μL of a vigorously shaken solution of CuI 
(500 mM in H2O) and 5 μL of nitrogenous base (TEA or pyrrolidine, 500 mM in H2O). 
The two solutions were thoroughly mixed by pipetting. Next, reaction partners 1 and 2 
were added and mixed by pipetting. Reaction partners consisted of GFP containing 
alkyne or bromoalkyne UAAs at varying positions (20 μL, ~1 mg/mL in PBS), or alkyne 
DNA oligonucleotide (15 μL, 100 μM in H2O). In reactions involving linkers, 5 μL of 
100 μM linker dissolved in DMSO was added. The reaction was incubated at 4°C for 4 
hours. The reaction was stopped either by performing SDS-PAGE immediately or by 
removing excess reactants via buffer exchange using Spin-X UF concentrator columns, 
and then subsequently analyzing the purified products by SDS-PAGE.   
 
General Procedure for Biological 1,3-Dipolar Azide-(Bromo)alkyne Cycloaddition: 
To a sterile 1.5 mL eppendorf tube, the following were added: 2 μL of CuSO42 (50 mM 
in H2O), 2 μL of TCEP (50 mM in H2O). Next, reaction partners 1 and 2 were added to 
the mixture and mixed by pipetting. Reaction partners consisted of GFP151 containing 
either azide or bromoalkyne UAA (20 μL in PBS), Ub48/pAzF (15 μL in PBS), or 
AlexaFluor 488 Azide (10 μL, 1 mM in DMSO). Lastly, 10 μL of TBTA (5 μM in 
DMSO) was added, followed by 20 μL PBS. In reactions involving linkers, 5 μL of 100 
μM linker dissolved in DMSO was added. The reaction was incubated at 4°C for 16 
hours. The reaction was stopped either by performing SDS-PAGE immediately or by 
removing excess reactants via buffer exchange using Spin-X UF concentrator columns, 
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and then subsequently analyzing the purified products by SDS-PAGE.   
 
General Procedure for Biological Thiol-yne Reaction26: To a sterile 1.5 mL eppendorf 
tube, the following were added: 30 μL dansyl-glutathione (dGSH) in PBS and 10 μL 
TCEP (50 mM in H2O). The solution was incubated at room temperature for 2 hours to 
ensure any oxidized dGSH was sufficiently reduced. To another eppendorf tube, the 
following were added to make a Tris-HCl reaction buffer: 6 μL of 1 M Tris-HCl 
(pH=6.8), 10 μL of 10 mM TCEP in H2O, 10 μL of 10% SDS, and 24 μL of H2O. To the 
Tris-HCl buffer was added 6.25 μL of 2,2-dimethoxy-2-phenylacetophenone (DPAP). To 
control reactions, 6.25 μL of H2O was added instead of DPAP. In another eppendorf tube, 
5 μL of the DPAP/Tris-HCl buffer solution was added to 20 μL of GFP151/pPrF, and the 
resulting solution was incubated at room temperature for 10 minutes. Next, 20 μL of the 
dGSH thiol substrate solution was added, and the resulting solution was incubated at 
room temperature for another 10 minutes. The reaction was irradiated at 365 nm for 6 
minutes and then incubated at room temperature for 5 minutes. The reaction was heated 
to 98°C for 10 minutes and then analyzed via SDS-PAGE.  
 
General Procedure for Biological Pyrrole-forming Reaction: To a sterile 1.5 mL 
eppendorf tube, the following were added: 10 μL of GFP151/pPrF—AlexaFluor 488 
Alkyne dimer, 3 μL of a vigorously shaken solution of CuI (500 mM in H2O), 5 μL of 
amine DNA oligonucleotide (10 μM in H2O), and 2 μL PBS. The reaction was incubated 
at 37°C for 12 hours. The products were heat denatured at 98°C for 10 minutes and 
analyzed by SDS-PAGE. No multivalent product was detected. 
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General Procedure for Biological Sonogashira Coupling Reaction25: A catalyst 
mixture was prepared as follows: Equivolumetric amounts of palladium (II) acetate 
(Pd(OAc)2, 10 mM in 1:1 H2O/DMSO) and triphenylphosphine-3,3′,3′′-trisulfonic acid 
trisodium salt (TPPTS, 50 mM in H2O) were mixed in a sterile 1.5 μL eppendorf tube. 
Another solution of copper (II) triflate (CuOTf, 20 mM in DMSO) was prepared in a 
separate tube. The two resulting solutions were combined to create a 5:1 volumetric ratio 
of Pd(OAc)2/TPPTS to CuOTf. To 5 μL of this resulting catalyst solution was added 10 
μL of a bromotriazole-containing dimer of GFP151/pBrPrF and AlexaFluor 488 Azide. 
Next, 10 μL of the third reaction partner, consisting of either GFP151/pPrF, alkyne DNA 
oligonucleotide (100 μM in H2O), or akyne PEG (10 μM in DMSO), was added. Lastly, 5 
μL of PBS was added to bring the total volume up to 25 μL. The reactions were 
incubated for 1 hour at room temperature, and excess reactants were removed via buffer 
exchange using Spin-X UF concentrator columns. The products were heated to 98°C for 
10 minutes and analyzed by SDS-PAGE. No multivalent product was detected. 
 
General Procedure for Biological Tetrazine Ligation: To a 1.5 μL sterile eppendorf 
tube, GFP151/pPrF (15 μL) was mixed with 3,6-di-2-pyridyl-1,2,4,5-tetrazine (10 μL, 10 
mM in DMSO). The reaction was incubated at room temperature for 1 hour and 
subsequently rinsed 5 times with PBS to a final reaction volume of 50 μL. Next, 10 μL of 
the solution was added to a quartz cuvette and diluted to 2 mL with PBS. The cuvette was 
excited with light at 395 nm with a 10 nm slit width and at a scan speed of 500 nm/min. 
The fluorescence emission spectrum did not show any shift from unreacted 
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GFP151/pPrF, which indicates that no reaction occurred.  
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Figure 5.1. The CRISPR-mediated bacterial immune response to invading viruses.3 
CHAPTER 5: PROBING CRISPR/CAS9 WITH UNNATURAL AMINO ACIDS 
Introduction 
The CRISPR/Cas9 system has received significant attention in modern science 
because of its ability to enable precise genome engineering. CRISPR, which stands for 
“clustered regularly interspaced short palindromic repeats,” evolved as a bacterial 
immune response against invading viruses.1 The CRISPR/Cas9 immune response 
employs Cas9, an RNA-guided nuclease, to detect and cleave foreign viral DNA in order 
to prevent a virus from overtaking a host cell. The specificity with which CRISPR/Cas9 
targets and cleaves specific DNA sequences implicates this technology as a revolutionary 
means of treating disease by correcting deleterious genetic mutations.2  
 The mechanism by which CRISPR/Cas9 recognizes and destroys foreign DNA in 




When a virus inserts double-stranded DNA into the cell, Cas9 processes the DNA to 
create a novel “spacer” into the CRISPR locus of the bacterial genome.4 Transcription of 
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the spacer in the CRISPR locus gene results in a CRISPR-associated RNA (crRNA), 
which pairs with a tracrRNA. Together, the crRNA:tracrRNA complex both binds Cas9 
and hybridizes with foreign viral DNA,  which brings Cas9 into the proper orientation to 
cleave the DNA. Many spacers originating from different viral DNA strands can be 
incorporated into the CRISPR locus with repeated sequences in between, thereby creating 
a library of crRNAs that recognize DNA from viruses that have previously infected the 
bacteria.2  
 The bifunctional structure of Cas9 allows it to act as both a DNA binder and 
endonuclease, providing it with the ability to recognize and destroy exogenous viral 
DNA. The crystal structure of Cas9 isolated from S. pyogenes reveals a crescent-shaped 
protein with two lobes—a nuclease lobe (Figure 5.2, colored) and large α-helical lobe 
(Figure 5.2, gray)—that are connected by 
an arginine-rich region occurring between 
residues 59 and 76 (Figure 5.2, purple).1 
The nuclease lobe contains the pertinent 
catalytic domains, the HNH and RuvC 
domains, each of which cleave one strand 
of the double-stranded viral DNA; the HNH 
domain cleaves DNA complimentary to the 
guide crRNA:tracrRNA while the RuvC 
domain cleaves the noncomplementary 
strand.2 The RuvC domain resides at the bottom of a prominent groove on the nuclease 
lobe, while a wider groove in the α-helical lobe and is thought to bind the 
Figure 5.2. S. pyogenes Cas9 crystal structure 
showing pertinent lobes and catalytic domains.1 
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crRNA:tracrRNA complex through arginine residues 69, 70, 71, and 75. Upon binding of 
the RNA complex to the α-helical groove, Cas9 changes confirmation to align the RuvC 
domain across from the HNH domain, thereby creating a main channel where target DNA 
is aligned and cleaved.1   
While CRISPR/Cas9 systems of bacterial defense utilize a crRNA:tracrRNA 
complex to bind both DNA and Cas9 (Figure 5.3, right), a chimeric single-guide RNA 
(sgRNA) molecule is more often employed in molecular biology and gene editing 
experiments.2,5 The sgRNA is accomplished by fusing the 3’ crRNA sequence to the 5’ 
tracrRNA sequence with addition of a linker loop between the two RNA strands (Figure 









 Employing an RNA-guided wild-type Cas9 nuclease to edit DNA results in a 
double-stranded break, but single-stranded breaks can be accomplished with a Cas9 
nickase (nCas9, Figure 5.4).2  Mutation of either Asp to Ala at position 10, which 
eliminates the RuvC domain catalytic activity, or His to Ala at position 840, which 
eliminates the HNH domain catalytic activity, results in a single-stranded break.2 
Figure 5.3. Cas9 can be programmed with a single-guide RNA (left) by fusing the crRNA and 
tracrRNA to either side of a linker loop.5 
	   81 
Mutation of both D10 and H840 to alanine residues generates a catalytically-dead Cas9 
protein (dCas9, Figure 5.4). Though dCas9 cannot introduce any DNA breaks, it can still 
complex with sgRNA to bind target DNA sequences. Catalytically inactive dCas9 can 
been used to label chromosomal loci, transcriptionally activate or repress genes, and pull-








The application of CRISPR/Cas9 technology towards therapeutic interventions 
has been well documented. It has been employed to disable the genomes of Hepatitis B 
Virus (HBV), Human Papilloma Virus (HPV), and Human Immunodeficiency Virus 
(HIV) by inducing cell death through transcriptional interference or by inactivating pro-
viral DNA in cells where the DNA had not yet been integrated into the host genome.10 
Additionally, CRISPR/Cas9 was employed to successfully repair a cystic fibrosis-causing 
DNA deletion in the CTFR gene in intestinal stem cells, which enabled restored function 
of the gene.11 Most recently, this technology has enabled genome-wide screens to identify 
genes implicated in suppression or activation of neural toxicity, and to elucidate 
modulators of B-cell receptor signaling pathways 12, 13  
Figure 5.4. Functionality of wild type Cas9, nickases, and dCas9. 2 
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Despite the many reports of manipulating CRISPR/Cas9 to solve molecular 
biology problems, incorporation of UAAs into Cas9 to further probe its function has been 
limited, with only one reported experiment in the literature.14 In this experiment, 
optochemical control of Cas9 was demonstrated using a photocaged lysine (PCK) UAA 
near the sgRNA-Cas9 binding site. Upon ultraviolet irradiation, PCK reverted to 
endogenous lysine, thereby restoring the function of Cas9. The development of UAA-
containing Cas9 and dCas9 proteins remains an untapped opportunity for enhanced 
control of the powerful CRISPR/Cas9 machinery. By incorporating UAAs into Cas9, we 
hope to explore additional applications of a photoactivatable Cas9, using photosensitive 
UAAs, or immobilize dCas9 onto a solid support for DNA pull-down applications, 
among other applications. By installing new biochemistries into Cas9 via UAAs, we can 
extend this technology to a more diverse array of applications. 
 
Results and Discussion 
Site-Directed Mutagenesis and Protein Expression 
 To probe the functions of Cas9 and the catalytically inactive dCas9 using 
unnatural amino acids, key residues were targeted for site-directed PCR mutagenesis 
based on their role and/or location within the protein. Since our most successful 
suppression methodology to date utilizes an aminoacyl-tRNA/synthetase pair evolved to 
incorporate tyrosine derivatives, tyrosine residues—with the exception of the active 
site—were investigated for mutagenesis. This search identified five residues on which 
mutagenesis was subsequently performed and the amber stop codon, TAG, inserted 
(Figure 5.5) 















Residue D10, which is the active site involved in DNA cleavage, was selexcted, 
as insertion of a photo-caged UAA at this site may facilitate an experiment involving 
optical control of the nuclease function of Cas9. Additionally, Y72, which is adjacent to 
the arginine-rich region where the sgRNA:DNA hybridized complex is thought to bind, 
was picked, along with Y1131, which is also positioned near the bound sgRNA complex. 
Insertion of photo-caged UAAs at these sites may permit light-controlled binding of Cas9 
to nucleic acid. It has been reported that, upon binding of nucleic acid to Cas9, the 
orientation of Y450 undergoes a 120° conformational shift, so this residue was also 
selected for mutagenesis. 15 Lastly, Y1265, a surface-exposed tyrosine residue located far 
Figure 5.5. Ribbon diagram of five residues (red) selected for mutagenesis on protein Cas9 
(PDB-4ZT0).  Cas9 (blue) is shown in complex with single-guide RNA (orange). The figure 
was generated using the PyMOL molecular visualization software. 
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from the active site was chosen as a potential site for immobilization of Cas9 or dCas9 to 
a solid support. 
 With five sites chosen, site-directed mutagenesis primers were designed to allow 
for introduction of a TAG codon at positions 10, 72, 450, 1131, and 1265 in both Cas9 
and dCas9. Interestingly, the nucleic acid sequences of Cas9 and dCas9 were highly 
variable due to the codon bias. Therefore, different mutagenesis primers were designed 
for both Cas9 and dCas9 (see Materials and Methods). Site-directed mutagenesis was 
first performed on Cas9 using the KAPA HiFi polymerase and recommended 
mutagenesis procedure. Several attempts to create mutant plasmids revealed that addition 
of T4 DNA ligase was important for successful mutation. Nucleotide sequencing of the 
TAG-containing mutant plasmids verified that TAG insertion was successful at sites 10, 













Cas9 Y1131TAG Mutagenesis Cas9 Y1265TAG Mutagenesis
Original DNA sequence and nt position (5’ – 3’)
!
Forward primer (3’ – 5’)
Reverse primer (5’ – 3’)
Original AA sequence and position
New mutant DNA sequence (3’ – 5’)
Cas9 D10TAG Mutagenesis
Forward primer (3’ – 5’)
Reverse primer (5’ – 3’)
Original AA sequence and position
New mutant complimentary DNA sequence (3’ – 5’)




results of TAG 
insertion at 
residues 10, 
450, 1131, and 
1265 of Cas9. 
The new DNA 
sequence, which 
verifies the 
presence of the 
mutation, is 
shown at the 
bottom of each 
panel. The new 
sequence 
appearing in the 
top panels is the 
compliment 
(ATC) of the 
inserted 
mutation. 
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Mutagenesis was performed using the same protocol for dCas9. The mutant plasmids 
have not yet been sequenced to verify the presence of the TAG mutation, so negative 
control reactions (containing no KAPA polymerase) were performed to verify that the 
mutation was successful. Following PCR 
mutagenesis, E. coli BL21(DE3) competent 
cells were transformed with the mutant 
plasmids from positive and negative controls 
and plated on agar containing an antibiotic. 
Differential bacterial colony growth between 
the positive and negative control would 
indicate that TAG was successfully inserted at the desired position (Figure 5.7); 
therefore, the degree of differential growth reflects our level of certainty that the mutation 
was successful. The bacterial growth was determined to be highly differential for Y1265 
and Y1131, moderately differential for D10 and Y450, and poorly differential for Y72.  
 With TAG-containing plasmids encoding Cas9 and dCas9 on hand, we next 
attempted to express UAA-containing Cas9 and dCas9 protein. We previously 
determined that expression of WT protein was optimal using 
large 100 mL expression cultures, given the energetic cost to 
the bacteria to synthesize an exogenous 160 kDa protein. 
Mutant plasmids Cas9-D10TAG, Cas9-Y450TAG, Cas9-
Y1131TAG and Cas9-Y1265TAG were each co-transformed 
with a plasmid encoding pCNF, a polyspecific orthogonal 




Figure 5.X. Structure of UAA pAzF 
used for incorporation into Cas9.
Figure 5.7. Example of differential colony 
growth between positive (left) and negative 
(right) control mutagenesis experiments for 
dCas9-Y1265TAG. 
Figure 5.8. Structure of 
UAA pAzF used for 
incorporation into Cas9. 
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TAG codon. The azido UAA pAzF (Figure 5.8) was introduced into the expression 
cultures, and protein was purified via nickel resin-based affinity chromatography, which 
was facilitated by a hexa-histidine purification tag present at the end of the protein. The 
eluted protein fractions were then analyzed by SDS-PAGE. Unfortunately, two 
expression trials resulted in no mutant protein containing pAzF at positions 10, 450, or 















A possible explanation for these results is that UAAs simply cannot be 
incorporated into certain positions in proteins with high fidelity, due to the role of some 
residues in post-translational processing and folding. Since residues D10, Y450, and 
Lane																						1							2							3								4							5								6								7								8							9
pAzF +								+							+								+									- - - -
L						FT																																			FT
150kDa





Figure 5.9. SDS-PAGE showing purified Cas9 expressions of A) Cas9-Y450TAG, B) Cas9-
Y1131TAG, and C) Cas9-D10TAG. No usable protein was observed, as evidenced by a lack of 
defined bands near 160 kDa, which is the molecular weight of Cas9. “L” denotes the molecular 
weight marker, and “E1-E4” denotes eluted protein fractions 1-4. 
Figure 5.10. SDS-PAGE showing expression of Cas9 containing pAzF at 
position 1265. “L” denotes the molecular weight marker, and “FT” denotes 
flow through, or proteins and other cellular debris not captured by the cobalt 
resin.  
	   87 
Y1131 are in the interior of the protein, they may play a greater role in protein folding 
dynamics, as opposed to Y1265, which is a surface-exposed residue and was successfully 
targeted for UAA insertion. Further examination of expression conditions for these 
mutants must be performed to hopefully obtain usable amounts of these UAA mutant 
Cas9 proteins. 
Expression of WT protein was also performed to verify the expression protocol, 
which resulted in reasonably pure Cas9 and 
dCas9 protein after SDS-PAGE analysis 
(Figures 5.11). Protein expressions 
performed during this research also 
revealed two important considerations for 
successful expression of Cas9 protein. 
First, greater WT yields were 
accomplished by using a cobalt affinity 
resin for purification instead of a nickel affinity resin—which facilitates a more robust, 
albeit less selective purification—and by extending the initial incubation time of Cas9 
with the resin to over an hour. Second, buffer exchange of the Cas9 protein from 
imidazole-containing elution buffer into PBS should be performed in a 4°C refrigerated 
centrifuge with addition of cold PBS after each spin. Performing buffer exchange at room 









L E FT E
dCas9 Cas9
Figure 5.11. SDS-PAGE showing WT dCas9 and 
WT Cas9 protein. “L” denotes ladder, “FT” denotes 
flow through, or proteins and cellular debris not 
captured by the cobalt resin, and “E” denotes 
protein eluted from the resin. 
	  









In order to test the nuclease function of our purified WT Cas9 samples, we 
performed a cleavage assay on a target DNA plasmid. It was imperative to verify that our 
Cas9 purifications could indeed selectively cleave DNA before attempting to employ 
UAA-containing Cas9 in photo-caging or immobilization applications. To assay the 
cleavage activity of Cas9, three elements are needed: an sgRNA strand, a target DNA 
strand capable of hybridizing to the sgRNA, and the WT Cas9 itself. A 121-base sgRNA 
(EGFP-gRNA7) was designed based on an experiment involving Cas9 reported in the 
literature; the sgRNA was obtained as a single-stranded DNA oligomer.14 This DNA 
oligomer was amplified by PCR and analyzed by agarose gel electrophoresis (Figure 
5.12, A). The plasmid pIRG (Figure 5.13), which hybridizes to the synthetic sgRNA, was 
obtained as the target DNA to be cleaved. Before employing pIRG in cleavage reactions, 
the plasmid was linearized with the restriction enzyme XhoI. In plasmid form, pIRG most 
likely takes on several different supercoiled formations that, when analyzed on an 
agarose gel, migrated to different molecular weights, resulting in several bands (Figure 
5.12, B, Lane 2). After successful linearization, pIRG appeared as a single band (Figure 







Figure 5.12. A) 
Agarose gel showing 
EGFP-gRNA7 PCR 
product and T7 
promoter DNA 
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With amplified sgRNA in DNA form, 
linearized pIRG, and WT Cas9 in PBS on hand, 
cleavage reactions were performed to verify that 
Cas9 would selectively cleave the DNA target. 
The sgRNA was transcribed from DNA to RNA 
using an in vitro transcription kit and then 
incubated with Cas9 to facilitate pre-annealing of 
the sgRNA-Cas9 complex. If DNase was used during the transcription reaction to remove 
the DNA template, it had to be removed prior to cleavage reactions, as residual DNase 
degraded the target DNA. Control reactions were performed using deionized water 
instead of Cas9. Either linearized pIRG or plasmid pIRG was added, and the reaction was 
incubated at room temperature 
overnight. Successful cleavage of 
linearized pIRG by Cas9 would be 
confirmed by two bands on an agarose 
gel, and cleaved plasmid pIRG would 
appear as a single band rather than an 
array of several supercoiled plasmid 
bands.  
Analysis by agarose gel 
electrophoresis revealed total 
degradation of linearized or plasmid 
pIRG when Cas9 was present, 
Figure 5.13. Plasmid map of pIRG. 
Lane 1 2 3 4 5 6 7
Ladder + - - - - - -
WT Cas9 - - - + - + -
pIRG, plasmid - + - - - + +
pIRG, linear - - + + + - -






Figure 5.14. Agarose gel of products of cleavage assay 
performed on linearized pIRG (lanes 4-5) and plasmid 
pIRG (lanes 6-7). Results indicate multiple, non-specific 
cuts of DNA by Cas9, as shown by undetectable target 
DNA in the experimental lanes (4, 6). 
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potentially due to off-site and nonspecific cleavage by Cas9 (Figure 5.14). Further 
research may include optimization of the WT Cas9 cleavage assay with redesigned 
sgRNA prior to unnatural amino acids being incorporated for photocontrol and 
immobilization applications.  
  
Materials and Methods 
Site-Specific DNA Mutagenesis 
General Protocol for PCR Mutagenesis: PCR mutagenesis was performed in a 
Bio-Rad iCycler 96 well reaction module thermocycler. The protocol was adapted from 
the KAPA Polymerase HiFi PCR mutagenesis protocol. Two, 1x master mix for the PCR 
reaction were created by adding 5 µL KAPA HiFi Buffer, 0.75 µL 10 mM dNTPs, 0.75 
µL of 10 mM of forward primer dissolved in sterile deionized water, 0.75 µL of 10 mM 
of reverse primer also dissolved in sterile deionized water, and 12.25 µL of sterile 
deionized water. To the reaction master mix was added 0.5 µL of KAPA polymerase at 
the very end, prior to starting the reaction in the thermocycler. To the control master mix 
was added 0.5 µL of sterile deionized water in place of the KAPA polymerase. To 
nuclease-free PCR tubes, 10 ng of template DNA (5 µL, 1 ng/µL) was added, followed 
by 20 µL of either control or master reaction mix. The tubes were then loaded into the 
thermocycler using the following protocol: 1) initial denaturation at 95°C for 2 mins; 2) 
denaturation at 98°C for 20 secs followed by annealing at the Tm (melting temperature) 
specific to the primers (provided by IDT) for 15 secs followed by an extension at 72°C 
for 4.5 mins (30 sec/kbp), this step was cycled for a total of 20 cycles; 3) a final extension 
was performed at 72°C for 5 mins; 4) the thermocycler completed the run by holding at 
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4°C. Following the PCR mutagenesis, 1 µL of DpnI, 1 µL of DNA T4 ligase, and 4 µL 
DNA T4 ligase buffer were added to the samples to remove any methylated template 
DNA and ligate the newly formed DNA. The samples were incubated at 37°C for 2 hours 
and then at 80°C for 15 mins to deactivate the enzymes. The samples were then PCR 
cleaned and concentrated (Zymo Research DNA clean and Concentrator Kit) and eluted 
in 10 µL of sterile deionized water. Two microliters of each sample were then 
transformed into competent E. coli (BL21(DE3)), recovered in 500 µL of LB media for 1 
hour, and then this full volume was plated on agar plates supplemented with antibiotics 
(kanamycin for Cas9, ampicillin for dCas9). After allowing colonies to grow overnight, 
plates were compared for differential growth between the reaction and control. If 
differential growth was observed, four colonies were picked at random in four different 
quadrants of the plate. These were grown to confluence overnight at 37°C, a glycerol 
stock was prepared using 1 mL of culture, while the rest was used to extract DNA for 
sequencing and expression tests.  
Protein Plasmids: Plasmids encoding Cas9 and dCas9 were obtained from the 
plasmid depository Addgene. The plasmid pET-28b-Cas9-His (#47327) was used for 
expression and mutagenesis of Cas9; this plasmid is formed from a pET-28b vector 
backbone and contains kanamycin resistance. A second plasmid encoding Cas9, pET-
NLS-Cas9-6xHis (#62934) was also obtained but not utilized in experiments; this 
plasmid is formed from a pET29 vector backbone and contains ampicillin resistance. The 
plasmid pET-dCas9-VP64-6xHis (#62935) was secured for mutagenesis and expression 
of dCas9; this plasmid is formed from a pET29 vector backbone and contains ampicillin 
resistance. 
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PCR Primer Sequences: The table below displays sequences of the forward and 
reverse primers for mutagenesis of Cas9 and dCas9.  
Mutation Direction Template Plasmid Tm (°C) Sequence 
Cas9-D10TAG Forward pET-28b-Cas9-His 67.3 5’-aagtactccattgggctctagatc 
ggcacaaacagcgtc-3’ 
Cas9-D10TAG Reverse pET-28b-Cas9-His 67.3 5’-gacgctgtttgtgccgatctagag 
cccaatggagtactt-3’ 
Cas9-Y72TAG Forward pET-28b-Cas9-His 68.0 5’-gaacagcacggcgcagatagac 
ccgcagaa-3’ 
Cas9-Y72TAG Reverse pET-28b-Cas9-His 68.0 incorrect primer sequence 
Cas9-Y450TAG Forward pET-28b-Cas9-His 64.5 5’-catttcggataccctagtatgtagg 
ccccctcg-3’ 
Cas9-Y450TAG Reverse pET-28b-Cas9-His 64.5 5’-cgagggggcctacatactaggg 
tatccgaaatg-3’ 
Cas9-Y1131TAG Forward pET-28b-Cas9-His 66.2 5’-agattgggaccccaagaaatagg 
gcggattcga-3’ 
Cas9-Y1131TAG Reverse pET-28b-Cas9-His 66.2 5’-tcgaatccgccctatttcttgggg 
tcccaatct-3’ 
Cas9-Y1265TAG Forward pET-28b-Cas9-His 63.2 5’-acacaaacactagcttgatgaga 
tcatcgagcaaataagc-3’ 
Cas9-Y1265TAG Reverse pET-28b-Cas9-His 63.2 5’-gcttatttgctcgatgatctcatca 
agctagtgtttgtgt-3’ 
dCas9-D10TAG Forward pET-dCas9-VP64-6xHis 64.9 5’-caactgaattggtgccgatctaca 
ggccgatactgtattttt-3’ 
dCas9-D10TAG Reverse pET-dCas9-VP64-6xHis 64.9 5’-aaaaatacagtatcggcctgta 
gatcggcaccaattcagttg-3’ 
dCas9-Y72TAG Forward pET-dCas9-VP64-6xHis 67.5 5’-cttacgacgtgtctagcgacggc 
gggc-3’ 
dCas9-Y72TAG Reverse pET-dCas9-VP64-6xHis 67.5 5’-gcccgccgtcgctagacacgtcg 
taag-3’ 
dCas9-Y450TAG Forward pET-dCas9-VP64-6xHis 62.7 5’-ccagaggaccgacatactaaggg 
atacgaaatgt-3’ 
dCas9-Y450TAG Reverse pET-dCas9-VP64-6xHis 62.7 5-acatttcgtatcccttagtatgtcgg 
tcctctgg-3’ 
dCas9-Y1131TAG Forward pET-dCas9-VP64-6xHis 63.8 5’-caaaaaagatttgggatccga 
aaaaatagggtggcttcgattc-3’ 
dCas9-Y1131TAG Reverse pET-dCas9-VP64-6xHis 63.8 5’-gaatcgaagccaccctattttttcg 
gatcccaatcttttttg-3’ 
dCas9-Y1265TAG Forward pET-dCas9-VP64-6xHis 60.3 5’-gtttgtggagcagcataagcatta 
gttagatgag-3’ 
dCas9-Y1265TAG Reverse pET-dCas9-VP64-6xHis 60.3 5’-ctcatctaactaatgcttatgctcgt 
ccacaaac-3’ 
 
Plasmid Sequencing: Cas9-containing plasmids were purified from bacterial 
cultures (Promega) and prepared according to the GENEWIZ sample submission 
guidelines. Plasmids Cas9-D10TAG and Cas9-Y72TAG were sequenced with the 
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GENEWIZ universal T7 promoter primer. Plasmids Cas9-Y1131TAG and Cas9-
Y1265TAG were sequenced with the GENEWIZ universal T7 terminator primer. 
Plasmid Cas9-Y450TAG was sequenced with a custom primer with the following 
sequence: 5’-TTCTGCTGAGTGATATTCTGCG-3’. Prepared samples were submitted 
to GENEWIZ for sequencing. 
 
Expression of WT or UAA-containing Cas9 and dCas9: A plasmid containing WT or 
mutant protein sequences (pET-28b-Cas9-His or pET-dCas9-VP64-6xHis or mutated 
plasmids, 0.5 µL) was co-transformed with a pEVOL-pCNF plasmid (0.5 µL) into 
Escherichia coli BL21(DE3) cells using an Eppendorf eporator. The cells were then 
plated and grown on LB agar in the presence of chloramphenicol (34 µg/mL) and, 
depending on plasmid-encoded resistance, either kanamycin (100 µg/mL) or ampicillin 
(50 µg/mL) at 37 ̊ C overnight. One colony was then used to inoculate LB media (10 mL) 
containing both kanamycin and, depending on plasmid-encoded resistance, ampicillin or 
chloramphenicol. The culture was incubated at 37 ̊ C overnight and used to inoculate an 
expression culture (100 mL LB media, 100 µg/mL Kan, 34 µg/mL Chlor, or 50 µg/mL 
Amp) at an OD600 0.1. The cultures were incubated at 37 ̊ C to an OD600 of 0.6. For 
expressions of UAA-containing protein, expression was induced by addition of UAA (1 
mL, 100 mM) and 20 % arabinose (100 µL) and 0.8 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG; 100 µL). For expressions of WT protein, expression was 
induced by addition of 20 % arabinose (100 µL) and 0.8 mM IPTG (100 µL). The 
cultures were incubated at room temperature for 24 h then centrifuged at 5,000 rpm for 
20 minutes and stored at -80 ̊ C. To purify the protein, the cell pellet was resuspended 
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using 500 µL of Bugbuster (Novagen) containing lysozyme and 200 µL lysis buffer, and 
incubated at RT for 30 minutes. The solution was then centrifuged at 5,000 rpm for 20 
mins. The supernatant was added to an equilibrated spin column containing HisPur 
Cobalt Resin (Thermo Fisher Scientific). The initial incubation of supernatant and resin 
was performed for 1.5 hours at RT with shaking. Cas9 was then purified according to 
manufacturer’s protocol. Purified GFP was analyzed by SDS-PAGE and employed 
without further purification. 
Cleavage Assay 
 PCR Amplification: PCR amplification was performed in a Bio-Rad iCycler 96 
well reaction module thermocycler. The protocol was adapted from the KAPA HiFi 
Polymerase PCR amplification protocol. A 1x master mix was created by adding 5 µL 
KAPA HiFi Buffer, 0.75 µL 10 mM dNTPs, 0.75 µL of 10 mM of T7 forward primer 
dissolved in sterile deionized water, 0.75 µL of 10 mM of T7 reverse primer also 
dissolved in sterile deionized water, and 12.25 µL of sterile deionized water. To this 
solution was added 1 ng EGFP-gRNA7 template DNA (5 µL of 0.2 ng/µL). The tubes 
was then loaded into the thermocycler using the following protocol: 1) initial 
denaturation at 95°C for 3 mins; 2) 20 cycles of: denaturation at 98°C for 20 secs, 
annealing at 52.3° for 15 secs, and extension at 72°C for 15 secs; 3) final extension at 
72°C for 1 min; 4) the thermocycler completed the run by holding at 4°C. The samples 
were then PCR cleaned and concentrated (Zymo Research DNA clean and Concentrator 
Kit) and eluted in 20 µL of sterile deionized water. The concentration was determined 
using a NanoDrop 2000 Spectrophotometer (Thermo Fischer Scientific), and the sample 
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was also run on a 1.5% agarose gel to assess PCR amplification efficiency. Sequences for 
the EGFP-gRNA7 template and PCR primers are displayed in the table below.14 





T7 forward primer 5’-taatacgactcactataggg-3’ 47.5 
T7 reverse primer 5’-aaagcaccgactcggtgcca-3’ 62.1 
 
 Plasmid Linearization: To a PCR tube, the following was added: 1 µg of pIRG 
plasmid, 5 µL of 10X CutSmart Buffer (New England BioLabs), and diH2O up to 49 µL. 
One microliter of restriction enzyme XhoI (New England BioLabs) was added (for a 50 
µL total reaction volume), and the solution was thoroughly mixed by pipetting. The tube 
was incubated at 37°C for 1 hour and then at 65°C for 20 minutes to inactivate the 
enzyme. The sample was then PCR cleaned and concentrated (Zymo Research DNA 
Clean & Concentrator Kit) and eluted in 10 µL of Cas9 activity buffer (20 mM HEPES, 
150 mM KCl, 0.5 mM DTT, 0.1 mM EDTA, 10 mM MgCl2, pH 7.4). The product was 
run on a 1% agarose gel containing EtBr to assess linearization efficiency.  
 Cleavage Reactions:  The EGFP-gRNA7 DNA template (100 ng) was transcribed 
to RNA using the MEGAscript T7 transcription kit (Life Technologies) according to the 
manufacturer’s protocol, excluding the addition of TURO DNase. The cleavage reactions 
were created by adding the following to a PCR tube: 1 µL (12,000-16,000 ng) of 
unpurified synthetic gRNA, 2 µL of TAE/Mg2+ buffer (40 mM tris-acetate, 1 mM EDTA, 
12.5 mM magnesium acetate), and 40 µL WT Cas9. For control reactions, WT Cas9 was 
replaced with diH2O. The solution was incubated at RT for 30 minutes to facilitate 
annealing of the gRNA to Cas9. Next, 750 ng of target DNA (pIRG, 5 µL of 150 ng/µL, 
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either linearized or supercoiled) in Cas9 activity buffer (20 mM HEPES, 150 mM KCl, 
0.5 mM DTT, 0.1 mM EDTA, 10 mM MgCl2, pH 7.4) was added. The tubes were 
incubated at 37°C for 16 hours, then at 72°C for 20 minutes, and finally held at 4°C. The 
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CHAPTER 5: UTILIZATION OF MICROWAVE CHEMISTRY FOR FISCHER 
ESTERIFICATION REACTIONS 
Introduction 
In the past 30 years microwaves have found widespread use in organic chemistry.1 
Microwave irradiation directly interacts with both the solvent and reactants, providing a 
mechanism for the efficient heating of reactions.2 Overall, microwave reactors offer key 
advantages, such as the ability to significantly reduce reaction times and increase product 
yields.2 Through utilization of microwave technology, reaction times can be reduced from 
several hours to minutes and afford product in comparable yields.  
The traditional Fisher esterification is a hallmark of basic organic chemistry 
reactions, and therefore translating this reaction to a microwave setting perfectly 
illustrates these advantages. Microwave-assisted esterification reactions have previously 
been explored in the literature; however, this research will focus on the development of a 
general microwave esterification procedure for undergraduate organic chemistry 
laboratory experiments.3 Building upon previous microwave esterification laboratories, 
this research will also incorporate of an unknowns aspect to the experiment to further 
develop organic laboratory skills.  
Esters are compounds derived from the reaction of an acid and an alcohol. The 
Fisher esterification is a staple of many undergraduate organic laboratory courses due to 
its synthetic utility and its relevance to course materials. Moreover, it is a reaction that 
typically does not require extremely hazardous chemicals and long reaction times. 4 
Certain organic esters display a characteristic fragrance that is easily recognized and 
found in many artificial fruit flavorings.5 The sensory component of the laboratory is an 
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additional feature that engages students and confers a purpose to the laboratory beyond 
simply performing a reaction. In this experiment, a direct esterification reaction will be 
performed in the microwave reactor. Due to the use of microwave technology, there is no 
reaction apparatus setup and breakdown that comes with the standard esterification 
reaction, and the undergraduate student is able to focus on purification and unknown 
product analysis.  
 
            
The synthesis of esters may be carried out by numerous methods. When using 
acid and an alcohol, the reaction is referred to as a direct esterification (Figure 6.1). These 
reactions are also known as ester condensations due to the fact that water is always a 
byproduct of the reaction. In this 
experiment an ester will be synthesized 
using a direct esterification reaction, 
utilizing an unknown alcohol, acetic acid, 
and a catalytic amount of sulfuric acid. 
These reactions are generally in 
equilibrium, leading to yields of only 50-
70%, and often take several hours. By 
performing this reaction in a CEM 
Discover Microwave reactor (Figure 6.2). 










Figure	  6.2.	  CEM	  Discover	  Microwave	  Reactor.	  
Figure 6.1. Direct Esterification Reaction. 
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the yield and the drastically reducing the rate of the reaction. Moreover, the minimal 
scale utilized in the microwave represents a higher cost-efficiency and affords minimal 
waste relative to standard reflux experiments described in the literature.  
Results and Discussion 
A microwave esterification protocol was adapted from a previously reported CEM 
microwave experiment, but translated to a more general protocol for the use of various 
alcohols under identical conditions.6 Four alcohols were investigated for use in the 
unknowns experiment: octanol, propanol, isoamyl alcohol, and benzyl alcohol (Figure 
6.3). 
 
To a microwave vial, 0.75 mL of an unknown alcohol was added, followed by 1 
mL of acetic acid. Five drops of concentrated sulfuric acid were then added to the vial. 
Increased yields were found when 5-10 silica beads were added to adsorb water created 
during the direct esterification reaction. The vial was then inserted into the microwave 
reactor. The reaction time and temperature was varied in several trials. Ten minutes at 
Figure 6.3. Protocol for the microwave esterification including the alcohols used as unknowns and 
the corresponding synthesized esters. Each produced ester displays a distinct fruity smell; isoamyl 
acetate - banana, propyl acetate - pear, benzyl acetate - peach, and octyl acetate - orange. 
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130°C was found to be the most efficient time and temperature combination.  
Upon completion of irradiation, an extraction was performed using a solution of 
10% sodium bicarbonate and diethyl ether. The sodium bicarbonate was added first (10 
mL) to a 125 mL separatory funnel, and the reaction mixture added in portions. The 
reaction appeared effervescent, as the excess acid was then quenched by the sodium 
bicarbonate. Diethyl ether was then added (15 mL), shaken, and once the layers 
separated, the organic layer was collected. To the organic layer, an additional 5 mL of 
sodium bicarbonate, was added, and the organic layer was again collected. This process 
was repeated one more time. Next, the organic layer was dried with anhydrous MgSO4 
and filtered by gravity into a dry, pre-weighed, round-bottom flask. Excess solvent was 
removed in vacuo, and the flask was reweighed to determine the crude yield of the 
unknown ester.  
To ensure that the microwave procedure could provide a pure product in high 
yield, silica column chromatography using 5:1 hexanes:ethyl acetate was performed. 
Fractions containing ester producted were combined and the solvent was removed in 
vacuo. For all alcohols, NMR analysis showed the desired ester product with very 
minimal impurity. When performed by students, the resulting NMR spectrum can be used 
to identify the ester and subsequently the unknown alcohol used in the experiment. An 
example of the pure isoamyl alcohol NMR spectrum is shown is Figure 6.4, and the 
remaining NMR spectra are included in the Materials and Methods section. 
As another means of identification, the scent of the unknown ester products was 
tested. Octyl acetate gives off an orange aroma, while propyl acetate exudes a pear scent. 
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In conclusion, we have developed a generalized procedure for performing high-
yield microwave esterification reactions on four different alcohols. The microwave has 
proven to be useful in the formation of the desired unknown ester, drastically reducing 
the standard esterification reaction rate and producing similar or higher yields than those 
typically formed with the one-hour reaction time. Additionally, by using an unknown 
alcohol and producing an unknown ester, this experiment emphasizes product analysis 
and characterization skills.  
Materials and Methods 
Synthesis of Unknown Ester: To a microwave vial, 0.75 mL of an unknown alcohol was 
added, followed by 1 mL of acetic acid. Five drops of concentrated sulfuric acid were 
then added to the vial, followed by 5-10 silica beads. The vial was irradiated in a CEM 
Discover microwave reactor for 10 minutes at 130° C. The solution was extracted two 
times with diethyl ether and washed two times with a solution of 10% sodium 
bicarbonate. The organic layer was dried with MgSO4, filtered, and excess solvent was 
Figure 6.4. Sample 1H 
NMR obtained by the 
laboratory students. 
Pictured is isoamyl 
acetate.  
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removed in vacuo. The product was subjected to silica column chromatography using 5:1 
hexanes:ethyl acetate as the eluent. Excess solvent was removed in vacuo and the pure 






Figure 6.5. NMR spectrum of benzyl acetate. 
Figure 6.6. NMR spectrum of octyl acetate. 
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